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Guidelines summarize and evaluate available evidence with the aim of
assisting health professionals in proposing the best management
strategies for an individual patient with a given condition. Guidelines
and their recommendations should facilitate decision making of
health professionals in their daily practice. However, the final deci-
sions concerning an individual patient must be made by the
responsible health professional(s) in consultation with the patient
and caregiver as appropriate.
A great number of guidelines have been issued in recent years by
the European Society of Cardiology (ESC), as well as by other soci-
eties and organisations. Because of their impact on clinical practice,
quality criteria for the development of guidelines have been estab-
lished in order to make all decisions transparent to the user. The rec-
ommendations for formulating and issuing ESC Guidelines can be
found on the ESC website (http://www.escardio.org/Guidelines-&-
Education/Clinical-Practice-Guidelines/Guidelines-development/Writ
ing-ESC-Guidelines). The ESC Guidelines represent the official posi-
tion of the ESC on a given topic and are regularly updated.
The ESC carries out a number of registries which are essential to
assess, diagnostic/therapeutic processes, use of resources and adher-
ence to Guidelines. These registries aim at providing a better under-
standing of medical practice in Europe and around the world, based
on data collected during routine clinical practice.
The guidelines are developed together with derivative educational
material addressing the cultural and professional needs for cardiolo-
gists and allied professionals. Collecting high-quality observational
data, at appropriate time interval following the release of ESC
Guidelines, will help evaluate the level of implementation of the
Guidelines, checking in priority the key end points defined with the
ESC Guidelines and Education Committees and Task Force members
in charge.
The Members of this Task Force were selected by the ESC, includ-
ing representation from its relevant ESC sub-specialty groups, in
order to represent professionals involved with the medical care of
patients with this pathology. Selected experts in the field undertook a
comprehensive review of the published evidence for management of
a given condition according to ESC Committee for Practice
Guidelines (CPG) policy. A critical evaluation of diagnostic and thera-
peutic procedures was performed, including assessment of the
riskbenefit ratio. The level of evidence and the strength of the rec-
ommendation of particular management options were weighed and
graded according to predefined ESC scales, as outlined in tables 1 and
2 below.
The experts of the writing and reviewing panels provided declara-
tion of interest forms for all relationships that might be perceived as
real or potential sources of conflicts of interest. These forms were
compiled into one file and can be found on the ESC website (http://
www.escardio.org/guidelines). Any changes in declarations of interest
that arise during the writing period were notified to the ESC and
updated. The Task Force received its entire financial support from
the ESC without any involvement from the healthcare industry.
The ESC CPG supervises and coordinates the preparation of new
Guidelines. The Committee is also responsible for the endorsement
process of these Guidelines. The ESC Guidelines undergo extensive
review by the CPG and external experts. After appropriate revisions
the Guidelines are approved by all the experts involved in the Task
Force. The finalized document is approved by the CPG for publica-
tion in the European Heart Journal. The Guidelines were developed
after careful consideration of the scientific and medical knowledge
and the evidence available at the time of their dating.
The task of developing ESC Guidelines also includes the creation
of educational tools and implementation programmes for the recom-






















.slides, booklets with essential messages, summary cards for non-
specialists and an electronic version for digital applications
(smartphones, etc.). These versions are abridged and thus, for more
detailed information, the user should always access to the full
text version of the Guidelines, which is freely available via the
ESC website and hosted on the EHJ website. The National Societies
of the ESC are encouraged to endorse, translate and implement
all ESC Guidelines. Implementation programmes are needed
because it has been shown that the outcome of disease may be
favourably influenced by the thorough application of clinical
recommendations.
Health professionals are encouraged to take the ESC Guidelines
fully into account when exercising their clinical judgment, as well as in
the determination and the implementation of preventive, diagnostic
or therapeutic medical strategies. However, the ESC Guidelines do
not override in any way whatsoever the individual responsibility of
health professionals to make appropriate and accurate decisions in
consideration of each patient’s health condition and in consultation













Data derived from a single randomized clinical trial
or large non-randomized studies. 
Level of 
evidence C
Consensus of opinion of the experts and/or small studies, 
retrospective studies, registries.



















ns Class I Evidence and/or general agreement 
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Wording to use
Class III Evidence or general agreement that the 
given treatment or procedure is not 
useful/effective, and in some cases 
may be harmful.
Is not recommended
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..with that patient or the patient’s caregiver where appropriate and/or
necessary. It is also the health professional’s responsibility to verify
the rules and regulations applicable in each country to drugs and devi-
ces at the time of prescription.
2 Introduction
Supraventricular arrhythmias are common and patients are often
symptomatic, requiring management with drugs and electrophysio-
logical procedures. The ESC published management Guidelines for
supraventricular tachycardias (SVTs) in 20031; corresponding US
guidelines have also been published, the most recent being in 2015.2
There is a need to provide expert recommendations for professio-
nals participating in the care of patients presenting with SVT. In addi-
tion, several associated conditions where SVTs may coexist need to
be explained in more detail. To address this topic, a Task Force was
convened by the ESC, with the remit to comprehensively review the
published evidence and to publish Guidelines on the management of
patients with SVT, with up-to-date consensus recommendations for
clinical practice. This document summarizes current developments in
the field, with a focus on advances since the last ESC Guidelines were
published, and provides general recommendations for the manage-
ment of adults with SVT based on the principles of evidence-based
medicine.
2.1 Evidence review
Members of the Task Force were asked to perform a detailed litera-
ture review, weigh the strength of evidence for or against a particular
treatment or procedure, and include estimates of expected health
outcomes where data exist. Patient-specific modifiers, comorbidities,
and issues of patient preference that might influence the choice of
particular tests or therapies were considered, as were frequency of
follow-up and cost-effectiveness. In controversial areas, or with
regard to issues without evidence other than usual clinical practice,
consensus was achieved by agreement of the expert panel after thor-
ough deliberation. The document was peer-reviewed by official
external reviewers.
The strengths of the recommendations and levels of evidence of
particular management options were weighed and graded according
to predefined scales, as outlined above in Tables 1 and 2, respectively.
Overall, these Guidelines include evidence and expert opinions
from several countries. The pharmacological and non-
pharmacological antiarrhythmic approaches discussed may therefore
include drugs that do not have the approval of governmental regula-
tory agencies in all countries.
2.2 Relationships with industry and other
conflicts of interest
It is ESC policy to sponsor position papers and Guidelines without
commercial support, and all members volunteered their time. Thus,
all members of the writing group, as well as the reviewers, have dis-
closed any potential conflicts of interest in detail. The details of these
declarations will be posted on the ESC website upon publication of
these Guidelines.
2.3 What is new in the 2019 Guidelines?
2.3.1 Change in recommendations from 2003 to 2019
Owing to the fact that the previous Guidelines on SVT were pub-
lished 16 years ago, many drugs that were recommended at that time
are not considered in the 2019 Guidelines. In addition, techniques
and indications of ablation techniques have changed. These recom-
mendation changes are indicated for each section in Table 3 below.
Table 3 Changes in SVT Guidelines recommendations
since 2003
2003 2019
Acute management of narrow QRS
tachycardias
Verapamil and diltiazem I IIa
Beta-blockers IIb IIa
Amiodarone and digoxin are not mentioned in the
2019 Guidelines





Sotalol and lidocaine are not mentioned in the
2019 Guidelines
Therapy of inappropriate sinus
tachycardia
Beta-blockers I IIa
Verapamil/diltiazem and catheter ablation are not
mentioned in the 2019 Guidelines
Therapy of postural orthostatic tachy-
cardia syndrome
Salt and fluid intake IIa IIb
Head-up tilt sleep, compression stockings, selective
beta-blockers, fludrocortisone, clonidine, methyl-
phenidate, fluoxetine, erythropoietin, ergotamine/
octreotide, and phenobarbitone are not mentioned
in the 2019 guidelines.




Procainamide, sotalol, and digoxin are not men-
tioned in the 2019 Guidelines
Chronic
Beta-blockers I IIa
Verapamil and diltiazem I IIa
Sotalol and disopyramide are not mentioned in
the 2019 Guidelines
Therapy of atrial flutter
Acute








































..2.3.2 New recommendations in 2019 2.3.3 New revised concepts
• Drug therapy for inappropriate sinus tachycardia and focal atrial
tachycardia.
• Therapeutic options for acute conversion and anticoagulation of
atrial flutter.
• Therapy of atrioventricular nodal re-entrant tachycardia.
• Therapy of antidromic atrioventricular re-entrant tachycardia and
pre-excited atrial fibrillation.
• Management of patients with asymptomatic pre-excitation.
• Diagnosis and therapy of tachycardiomyopathy.
3 Definitions and classification
The term ‘SVT’ literally indicates tachycardia [atrial rates >100 beats
per minute (b.p.m.) at rest], the mechanism of which involves tissue
from the His bundle or above.2,3 Traditionally, SVT has been used to
describe all kinds of tachycardias apart from ventricular tachycardias
(VTs) and AF. It has therefore included tachycardias such as atrioven-
tricular (AV) re-entry due to accessory connections, which is not, in
Table 3 Continued
2003 2019
Verapamil and diltiazem I IIa
Beta-blockers I IIa
Digitalis is not mentioned in the 2019 Guidelines
Chronic
Dofetilide, sotalol, flecainide, propafenone, procai-
namide, quinidine, and disopyramide are not men-
tioned in the 2019 Guidelines
Therapy of AVNRT
Acute
Amiodarone, sotalol, flecainide, and propafenone
are not mentioned in the 2019 Guidelines
Chronic
Verapamil and diltiazem I IIa
Beta-blockers I IIa
Amiodarone, sotalol, flecainide, propafenone, and
the ‘pill-in-the pocket’ approach are not men-




Amiodarone, sotalol, and the ‘pill-in-the pocket’




Catheter ablation IIb IIa*
Sotalol, propranolol, quinidine, and procainamide
are not mentioned in the 2019 Guidelines.
*: when fluoroless ablation is available. AT = atrial tachycardia; AVNRT = atrio-
ventricular nodal re-entrant tachycardia; AVRT = atrioventricular re-entrant
tachycardia.
Table 4 New recommendations in 2019
Ivabradine alone or in combination with a beta-
blocker should be considered in symptomatic patients
with inappropriate sinus tachycardia.
IIa
Ibutilide (i.v.) ibutilide may be considered for acute
therapy of focal atrial tachycardia.
IIb
Ivabradine for postural orthostatic tachycardia syn-
drome, and ivabradine with a beta-blocker for chronic
therapy of focal atrial tachycardia, may be considered.
IIb
Patients with atrial flutter without AF should be con-
sidered for anticoagulation, but the threshold for ini-
tiation is not established.
IIa
Ibutilide (i.v.), or i.v. or oral (in-hospital) dofetilide are
recommended for conversion of atrial flutter.
I
High-rate atrial pacing is recommended for termina-




i.v. amiodarone is not recommended for pre-excited AF. III
Performance of an EPS to risk-stratify individuals with
asymptomatic pre-excitation should be considered.
IIa
Catheter ablation is recommended in asymptomatic
patients in whom electrophysiology testing with the
use of isoprenaline identifies high-risk properties, such
as SPERRI <_250 ms, AP ERP <_250 ms, multiple APs,
and an inducible AP-mediated tachycardia.
I
Non-invasive evaluation of the conducting properties
of the AP in individuals with asymptomatic pre-excita-
tion may be considered.
IIb
Catheter ablation may be considered in a patient with
asymptomatic pre-excitation and low-risk AP at inva-
sive or non-invasive risk stratification.
IIb
Catheter ablations should be considered in patients
with asymptomatic pre-excitation and LV dysfunction
due to electrical dyssynchrony.
IIa
AV nodal ablation with subsequent pacing (‘ablate and
pace’), either biventricular or His-bundle pacing, is
recommended if a tachycardia responsible for TCM
cannot be ablated or controlled by drugs.
I
During the first trimester of pregnancy, it is recommended
that all antiarrhythmic drugs are avoided, if possible.
I
In pregnant women, beta-1 selective blockers (except
atenolol) or verapamil, in order of preference, should
be considered for prevention of SVT in patients with-
out WPW syndrome.
IIa
In pregnant women, flecainide or propafenone should
be considered for prevention of SVT in patients with
WPW syndrome and without ischaemic or structural
heart disease.
IIa
AF = atrial fibrillation; AP = accessory pathway; AT = atrial tachycardia; AV =
atrioventricular; EPS = electrophysiology study; ERP = effective refractory period;
i.v. = intravenous; LV = left ventricular; POTS: postural orthostatic tachycardia
syndrome; SPERRI = shortest pre-excited RR interval during atrial fibrillation;



























essence, a supraventricular rhythm (Table 5). The term ‘narrow QRS
tachycardia’ indicates those with a QRS duration <_120 ms. A wide
QRS tachycardia refers to one with a QRS duration >120 ms
(Table 6). In clinical practice, SVT may present as narrow or wide QRS
tachycardias, most of which, although not invariably, manifest as regu-
lar rhythms. These Guidelines do not cover AF, which is the subject of




Arrhythmia can originate from abnormal impulse initiation in an individ-
ual myocyte or, more realistically, in a close cluster of myocytes. This
can occur in non-pacemaker cells through a mechanism similar to the
physiological automaticity of pacemaker cells [sinus node and AV node
(AVN)], and is thus named ‘abnormal’ or ‘enhanced automaticity’. An
alternative form of abnormal impulse initiation involves oscillations of
membrane potential, named early or delayed ‘after-depolarizations’. In
such cases, the resulting arrhythmias take the name of ‘triggered activ-
ity’.8 Arrhythmias resulting from enhanced automaticity and triggered
activity are defined as ‘non-re-entrant’. Arrhythmias can also arise
when myocardial regions activated later in propagation re-excite
regions that have already recovered excitability. This results from
abnormal propagation of the excitation wavefront and/or of tissue
refractoriness. This mechanism, named ‘re-entry’, is based on the syn-
cytial nature of myocardial tissue and is thus radically different from
focal impulse initiation.8 A detailed discussion and schematic represen-
tation of common SVT circuits is provided in the Supplementary Data.
Table 6 Differential diagnosis of narrow and wide QRS
tachycardias
Narrow QRS (120 ms) tachycardias
Regular
• Physiological sinus tachycardia
• Inappropriate sinus tachycardia
• Sinus nodal re-entrant tachycardia
• Focal AT
• Atrial flutter with fixed AV conduction
• AVNRT
• JET (or other non-re-entrant variants)
• Orthodromic AVRT
• Idiopathic VT (especially high septal VT)
Irregular
• AF
• Focal AT or atrial flutter with varying AV block
• Multifocal AT
Wide QRS (>120 ms) tachycardias
Regular
• VT/flutter
• Ventricular paced rhythm
• Antidromic AVRT
• SVTs with aberration/BBB (pre-existing or rate-dependent during
tachycardia)
• Atrial or junctional tachycardia with pre-excitation/bystander AP
• SVT with QRS widening due to electrolyte disturbance or antiarrhyth-
mic drugs
Irregular
• AF or atrial flutter or focal AT with varying block conducted with
aberration
• Antidromic AV re-entrant tachycardia due to a nodo-ventricular/fascic-
ular AP with variable VA conduction
• Pre-excited AF
• Polymorphic VT
• Torsade de pointes
• Ventricular fibrillation
Occasionally, AF with very fast ventricular response may apparently
resemble a regular narrow QRS tachycardia.
AF = atrial fibrillation; AP = accessory pathway; AT = atrial tachycardia; AV =
atrioventricular; AVNRT = atrioventricular nodal re-entrant tachycardia; AVRT =
atrioventricular re-entrant tachycardia; BBB = bundle branch block; JET = junc-
tional ectopic tachycardia; SVT = supraventricular tachycardia; VA = ventriculoa-
trial; VT = ventricular tachycardia.




• Physiological sinus tachycardia
• Inappropriate sinus tachycardia




• Cavotricuspid isthmus-dependent MRAT
 Typical atrial flutter, counter-clockwise (common) or clockwise
(reverse)
 Other cavotricuspid isthmus-dependent MRAT









• JET (junctional ectopic or focal junctional tachycardia)
• Other non-re-entrant variants
Atrioventricular re-entrant tachycardia (AVRT)
• Orthodromic (including PJRT)
• Antidromic (with retrograde conduction through the AVN or, rarely,
over another pathway)
AF = atrial fibrillation; AT = atrial tachycardia; AV = atrioventricular; AVN =
atrioventricular node; JET = junctional ectopic tachycardia; RA = right atrial; LA
= left atrial; MRAT = macro-re-entrant atrial tachycardia; PJRT = permanent junc-






























































..5 Cardiac anatomy for the
electrophysiologist
Knowledge of anatomical structures inside and outside the atrial
chambers is of clinical importance, especially when interventional




Epidemiological studies on the SVT population are limited. In the gen-
eral population, the SVT prevalence is 2.25/1000 persons and the
incidence is 35/100 000 person-years. Women have a risk of develop-
ing SVT that is two times greater than that of men, and persons aged
>_65 years or have more than five times the risk of developing SVT
than younger individuals. Patients with lone paroxysmal SVT vs. those
with cardiovascular disease are younger, have a faster SVT rate, have
an earlier onset of symptoms, and are more likely to have their condi-
tion first documented in the emergency department.9 In a paediatric
cohort study of 1 967 911 live births between 200008, 2021
patients (51.6% male, overall incidence 1.03/1000) had SVT
[Wolff-Parkinson-White (WPW) syndrome accounted for 16.2%].
By the age of 15 years, the annual risk of sudden death was 0.01% per
patient-year.10
In specialized centres, AVNRT is the most frequently treated sub-
strate after AF, followed by atrial flutter and AVRT, in patients
referred for catheter ablation.1113 Women are more likely to be
affected by AVNRT than men (ratio 70:30),1416 while the con-
verse is true for AVRT (ratio 45:55).14 A relationship with the
monthly cycle has been suggested,17 and episodes are more frequent
during pregnancy in women with pre-existing SVT.18
In the general population, the prevalence of a WPW pattern on
surface electrocardiogram (ECG) ranges from 0.150.25%,19
increasing to 0.55% among first-degree relatives of affected
patients.20 However, not all patients develop SVT and
intermittent pre-excitation is not rare. Compared with the remaining
population, the pre-excitation population is generally younger, pre-
dominantly male, and has less comorbidity.21,22 The proportion of
patients with AVRT decreases with age, whereas the proportion of
those with AVNRT and AT increases with age.14
The epidemiology of atrial flutter is not known with certainty, as
atrial flutter and AF can coexist. The prevalence of AF before flutter
ablation ranges from 2462%, and after ablation could be 3070%.
The overall incidence of atrial flutter is 88/100 000 person-years in
the US population annually. Adjusted for age, the incidence of atrial
flutter in men (125/100 000) is >2.5 times that of women (59/
100 000) and increases exponentially with age. Patients with atrial
flutter are more likely to have been smokers, have a longer PR inter-
val, history of myocardial infarction (MI), and history of heart failure
(HF).23
Catheter ablation is now used extensively for most varieties of
SVT, and patient-reported outcome measures have shown that
patients experience significant improvements in their quality of life
following ablation.2427 Patient-reported outcome measures using
various questionnaires are useful in the audit of ablation techniques.
Women are more often prescribed antiarrhythmic drugs before abla-
tion for SVT than men,28 and recurrence rates following AVNRT
ablation are higher in young women.29 However, overall, no signifi-
cant differences in health-related quality of life or access to healthcare
resources between men and women have been reported.28
7 Clinical presentation
The impact of SVT on an individual is based on a range of factors and
may result in palpitations, fatigue, light-headedness, chest discomfort,
dyspnoea, and altered consciousness.30 Rapid rhythms are more
likely to present with a clear history and acutely than less-rapid
rhythms, but SVT usually produces symptoms.31 The duration of
symptoms and the patient’s age at onset are important. An individual
with an onset in the teenage years or younger is less likely to have AT
or AF continuing into adulthood. Such a long history will point
towards a re-entrant mechanism.32 Dyspnoea, or other clinical signs
and symptoms of HF, can occur when the patient has developed
TCM. Light-headedness in association with SVT is not infrequent.30
Presyncope and syncope are less common,33,34 and tend to be asso-
ciated with presentation in older individuals.32 In older patients,
symptoms may be more extreme—with dizziness, presyncope, and
syncope—in view of the less-accommodating characteristics of the
circulation; drops in blood pressure are usually immediate and tend
to recover.35 In some patients, a description of polyuria (possibly due
to atrial stretch-induced atrial natriuretic peptide activity) can be elu-
cidated, although this is infrequent.36 Direct risks due to SVT are
unusual, but in specific situations (e.g. in patients with WPW syn-
drome and AF,22 or after atrial switch operation37) may lead to sud-
den cardiac death.
A sudden onset more likely points to AVNRT or AVRT, although
an AT may also present in this way.32 Characteristics in terms of the
regularity or irregularity are helpful. The duration of individual epi-
sodes may help in terms of differentiation. Re-entrant tachycardias
Table 7 Initial evaluation of the patient with supraven-
tricular tachycardia
Standard
• History, physical examination, and 12 lead ECG
• Full blood counts, biochemistry profile, and thyroid function
• An ECG during tachycardia should be sought
• Transthoracic echocardiography
Optional
• Exercise tolerance testing
• 24 h ECG monitoring, transtelephonic monitoring, or an implantable
loop recorder
• Myocardial ischaemia testing in patients with risk factors for coronary
artery disease (including men aged >40 years and post-menopausal
women)
• An EPS should be considered for a definitive diagnosis and when cathe-
ter ablation is anticipated
































































































tend to last longer than AT episodes, which may occur in a series of
repetitive runs.32 Clear descriptions of pounding in the neck (the so-
called ‘frog sign’) or ‘shirt flapping’ would point to the possible com-
peting influences of atrial and ventricular contraction on the tricuspid
valve, and to AVNRT as a likely cause.15,38,39
SVT may be unrecognized at initial medical evaluation and the clini-
cal characteristics can mimic panic disorder.40 In patients with possi-
ble sinus tachycardia in association with anxiety and postural
orthostatic tachycardia syndrome (POTS), it is important to rule out
the possibility of a re-entrant tachycardia.
8 Initial evaluation of patients with
supraventricular tachycardia
Complete history taking, including family history, and physical exami-
nation are essential. As discussed, clinical history is especially relevant
in cases of palpitations without ECG documentation of the tachycar-
dia. Initial evaluation points to a re-entrant arrhythmia when the
mode of onset/termination is sudden, is often associated with a
change of position, and the tachycardia is perceived as regular.
Initiation of the episode(s), frequency, and conditions of triggering
the arrhythmia are important clues for a specific diagnosis.3 There
may be evidence that specific actions lead to arrhythmia termination.
These could include standard vagal manoeuvres,41 but also abortive
measures such as drinking a glass of iced water. Also, responses to
the administration of drugs (e.g. adenosine or verapamil), where ter-
mination has been observed but ECGs are missing, may provide diag-
nostic help.
Full blood counts and a biochemistry profile—including renal func-
tion, electrolytes, and thyroid function tests—can be useful in specific
cases (Table 7). An ECG recorded during tachycardia is ideal, and
patients should be encouraged to seek medical assistance and
recording of their ECG during episodes. A 12 lead resting ECG and
baseline echocardiographic assessment are necessary. It may be use-
ful to do 24 h ECG recordings, but tachycardia episodes are usually
sporadic and may not be frequent enough to be recorded on ambula-
tory monitoring. Transtelephonic monitoring, mobile recording devi-
ces, or, very rarely, an implantable loop recorder may be required.
Wrist-worn, optically based heart rate monitors are user-friendly,
but appropriate validation of the device used is imperative.42 A toler-
ance exercise test may also be useful in patients with apparent pre-
excitation and in cases of catecholamine-dependent arrhythmias.
Myocardial ischaemia testing is also needed in patients with angina or
significant risk factors for coronary artery disease.43 An electrophysi-
ology study (EPS) is usually necessary to establish the diagnosis, par-
ticularly when catheter ablation is anticipated.
9 Differential diagnosis of
tachycardias
9.1 Narrow QRS (120 ms) tachycardias
Narrow QRS complexes are due to rapid activation of the ventricles
via the HisPurkinje system (HPS), which suggests that the origin of
the arrhythmia is above or within the His bundle. However, early
activation of the His bundle can also occur in high septal VTs, thus
resulting in relatively narrow QRS complexes (110140 ms).44
9.1.1 Electrocardiographic differential diagnosis
In the absence of an ECG recorded during the tachycardia, a 12 lead
ECG in sinus rhythm may provide clues for the diagnosis of SVT and
should be scrutinized for any abnormality. The presence of pre-
excitation in a patient with a history of regular paroxysmal palpitations is
generally suggestive of AVRT. The absence of apparent pre-excitation
does not rule out the diagnosis of AVRT, as it may be due to a con-
cealed accessory pathway (AP) that conducts only retrogradely or to
an atypical (Mahaim) pathway, which is latent at sinus rhythm.
An ECG taken during tachycardia is very useful in the efficient diag-
nosis of SVT, although it may fail to lead to a specific diagnosis.45 It
may not be available in patients with very short or infrequent periods
of palpitations.
9.1.1.1 Initiation and termination of the tachycardia
Sudden prolongation of the PR interval occurs in typical AVNRT after
an atrial ectopic beat. An AT may also be initiated by an atrial ectopic
beat, but is not dependent on marked PR prolongation. Automatic,
focal ATs are characterized by gradual acceleration (warm-up phe-
nomenon) followed by deceleration (cool-down phenomenon),46
and may also be incessant with short interruption by sinus beats.
Premature atrial or ventricular beats may trigger AVRT. Premature
ventricular complexes are a common trigger of atypical AVNRT, but
rarely induce typical AVNRT, and only exceptionally AT.
9.1.1.2 Regularity of tachycardia cycle length
The regularity of the RR interval should be assessed (Figure 1).
Irregular tachycardias may represent focal or multifocal AT, focal AF,
and atrial flutter with varying AV conduction. Patterns of irregularity
can sometimes be found, such as in atrial flutter conducted with
Wenckebach periodicity. Irregular arrhythmias, such as multifocal
AT, typically display variable P-wave morphologies, and varying PP,
RR, and PR intervals. Atrial flutter can have fixed AV conduction and
present as a regular tachycardia, and even AF may appear almost reg-
ular when very fast. Re-entrant tachycardias, whether micro or
macro-re-entries, are usually regular. Incessant tachycardias may be
the so-called permanent junctional reciprocating tachycardia (PJRT),
focal AT, or, rarely, atypical AVNRT. Cycle length (CL) alternans
(also called RR alternans) may be seen in AVNRT, but these changes
are <15% of the tachycardia CL.47 If the irregularity exceeds 15% of
the CL, a focal arrhythmia is much more likely.48 QRS alternans is a
rare phenomenon in slow SVTs, which may not be related to CL
alternans, and has been initially described with AVRT.49,50 However,
this may be seen in any fast SVT.51
A change in ventricular CL preceded by a change in atrial CL is
seen in AT or atypical AVNRT. A change in ventricular CL preceding
a change in subsequent atrial CL favours typical AVNRT or
AVRT.47,52 A fixed ventriculoatrial (VA) interval in the presence of
variable RR intervals excludes AT.45
9.1.1.3 P/QRS relationship
According to their P/QRS relationships, SVTs are classified as having






























































Figure 1 Differential diagnosis of narrow QRS tachycardia. Recording of a retrograde P wave should be sought by obtaining a 12 lead
Electrocardiogram and, if necessary, using the Lewis leads or even an oesophageal lead connected to a pre-cordial lead (V1) with use of alligator clamps.
The 90 ms cut-off is a rather arbitrary number used for surface electrocardiogram measurements if P waves are visible and is based on limited data. In the
electrophysiology laboratory, the cut-off of the ventriculoatrial interval is 70 ms. Junctional ectopic tachycardia may also present with atrioventricular dis-
sociation.
AF = atrial fibrillation; AT = atrial tachycardia; AV = atrioventricular; AVNRT = atrioventricular nodal re-entrant tachycardia; AVRT = atrioventricular re-

















shorter than one-half the tachycardia RR interval, whereas long-RP
SVTs display RP>_PR (Figure 1). Rarely, recording of U waves during
typical AVNRT may simulate a long-RP tachycardia.53
On EPS, a very short VA interval (<_70 ms) usually indicates typical
AVNRT, or less commonly focal AT, but has also been reported in
AVRT.54 For surface ECG measurements, a cut-off interval of 90 ms
has been shown to be useful and can be used if P waves are visible,55
but data on actual RP measurements during various types of SVT are
scarce.
P waves similar to those in normal sinus rhythm suggest appropri-
ate or inappropriate sinus nodal tachycardia, sinus nodal re-entrant
tachycardia, or focal AT arising close to the sinus node. P waves dif-
ferent from those in sinus rhythm, and conducted with a PR interval
equal to or longer than the PR in sinus rhythm, are typically seen in
focal AT. In AT, the conduction to the ventricles may be fast (1:1) or
slow (3:1 or 4:1). The possibility of atrial flutter with 2:1 conduction
should also be considered if the ventricular rate during SVT is 150
b.p.m., as the atrial activity is usually 250 - 330 b.p.m. In the presence
of antiarrhythmic medication in this setting, lowering the atrial rate
may result in a higher ventricular rate in the absence of AV nodal
blockade.
In the case of relatively delayed retrograde conduction that allows
the identification of retrograde P waves, a pseudo r deflection in lead
V1 and a pseudo S wave in the inferior leads are more common in
typical AVNRT than in AVRT or AT.56,57 These criteria are specific
(91100%) but modestly sensitive (58 and 14%, respectively).56 A
difference in RP intervals in leads V1 and III >20 ms is also indicative
of AVNRT rather than AVRT due to a posteroseptal pathway.57 The
presence of a QRS notch in lead aVL has also been found to be a reli-
able criterion suggesting AVNRT,58 while a pseudo r in aVR has been
shown to have greater sensitivity and specificity than a pseudo r in V1
for the diagnosis of typical AVNRT.59 However, in all referenced
studies, cases of AT or atypical AVNRT were limited or entirely
absent.
AV block or dissociation during narrow QRS tachycardia is not
often seen, but it rules out AVRT as both atria and ventricles are
parts of the circuit. The development of bundle branch block (BBB)
during SVT may also be helpful in the diagnosis of AVRT. BBB ipsilat-
eral to the AP can result in CL prolongation due to VA prolongation,
as the ventricular arm of the circuit is prolonged by conduction
through the interventricular septum from the conducting bundle
branch.60 However, it should be noted that lengthening of the VA
interval may not necessarily result in CL prolongation, due to a
potential switch of antegrade conduction from the slow to the fast
AV nodal pathway.
9.1.2 Vagal manoeuvres and adenosine
Vagal manoeuvres (such as carotid sinus massage) and adenosine
injection may help in clinical diagnosis, particularly in situations in
which the ECG during tachycardia is unclear. Possible responses to
vagal manoeuvres and adenosine are shown in Table 8 and Figure 2.
Termination of the arrhythmia with a P wave after the last QRS
complex is very unlikely in AT, and most common in AVRT and typi-
cal AVNRT. Termination with a QRS complex is often seen in AT,
and possibly in atypical AVNRT. Adenosine does not interrupt mac-
ro-re-entrant ATs (MRATs).61 Fascicular VTs, in particular, are
verapamil- but not adenosine-sensitive. Most VTs, as opposed to
SVTs, do not respond to carotid sinus massage, but a narrow QRS
VT originating at the left bundle branch and terminated with carotid
sinus massage has been reported.62
Table 8 Possible responses of narrow QRS tachycardia
to vagal manoeuvres and adenosine
(1) Slowing of AVN conduction and induction of intermittent AV block.
Atrial electrical activity can thus be unmasked, revealing dissociated P
waves (focal AT, atrial flutter, or AF waves).
(2) Temporary decrease in the atrial rate of automatic tachycardias (focal
AT, sinus tachycardia, and JET).
(3) Tachycardia termination. This can happen by interrupting the re-entry
circuit in AVNRT and AVRT by acting on the AVN that is part of the
circuit. More rarely, sinus nodal re-entry and ATs due to triggered
activity can slow down and terminate.
(4) No effect is observed in some cases.
AF = atrial fibrillation; AT = atrial tachycardia; AV = atrioventricular; AVN =
atrioventricular node; AVNRT = atrioventricular nodal re-entrant tachycardia;


































Figure 2 Responses of narrow-complex tachycardias to adenosine.
AT = atrial tachycardia; AV = atrioventricular; AVNRT = atrioventricular
nodal re-entrant tachycardia; AVRT = atrioventricular re-entrant tachy-










































Several electrophysiological techniques and manoeuvres can be
employed in the electrophysiology laboratory for differential diagno-
sis of regular narrow QRS tachycardia.45 A detailed discussion is
beyond the scope of these Guidelines.
9.2 Wide QRS (>120 ms) tachycardias
Wide QRS tachycardias can be VT, SVT conducting with BBB aberra-
tion, or antegrade conduction over an AP, with reported proportions
of 80, 15, and 5%, respectively.63 The correct diagnosis of a VT is crit-
ical to management, as misdiagnosis and administration of drugs usu-
ally utilized for SVT can be harmful for patients in VT.64 Therefore,
the default diagnosis should be VT until proven otherwise. The
differential diagnosis includes:65
(1) SVT with BBB. This may arise due to pre-existing BBB or the devel-
opment of aberrancy during tachycardia (so-called phase 3 block),
which is more commonly, although not invariably, a right BBB
(RBBB) pattern due to the longer RP of the right bundle branch.
(2) SVT with antegrade conduction over an AP, ‘pre-excited SVT’,
which participates in the circuit (antidromic AVRT) or is a bystander
during AF, focal AT/atrial flutter, or AVNRT.
(3) SVT with widening of QRS interval induced by drugs or electrolyte
disturbances. Class IA and IC drugs cause use-dependent slowing of
conduction, and class III drugs prolong refractoriness at
HisPurkinje tissue more than in the ventricular myocardium. They
can both result in atypical BBB morphologies during SVT that
mimics VT.
(4) Pacemaker-related endless loop tachycardia and artefacts, which
can also mimic VT.
9.2.1 Electrocardiographic differential diagnosis
If the 12 lead ECG is available in sinus rhythm, it can provide useful
diagnostic information. Specifically, if the QRS morphology is identical
during sinus rhythm and tachycardia, the arrhythmia is most likely not
a VT. However, bundle branch re-entrant VTs and high septal VTs
exiting close to the conduction system can have similar morphologies
to sinus rhythm. The presence of a contralateral BBB pattern in sinus
rhythm is more indicative of VT.
9.2.1.1 Atrioventricular dissociation
The presence of either AV dissociation or capture/fusion beats in the
12 lead ECG during tachycardia are key diagnostic features of VT. AV
dissociation may be difficult to recognize because P waves are often
hidden by wide QRS and T waves during a wide QRS tachycardia. P
waves are usually more prominent in inferior leads and in modified
chest lead placement (Lewis lead).63
The relationship between atrial and ventricular events is 1:1 or
greater (more atrial than ventricular beats) in most SVTs (Table 9).
AVNRT can be associated with 2:1 conduction,66 but this is rare.
Although VA conduction can be found in <_50% of patients with VT
and a 1:1 relationship is possible, most VTs have a relationship <1:1
(more QRS complexes than P waves).
9.2.1.2 QRS duration
A QRS duration >140 ms with RBBB or >160 ms with left BBB
(LBBB) pattern suggests VT. These criteria are not helpful for differ-
entiating VT from SVT in specific settings, such as pre-excited SVT,
or when class IC or class IA antiarrhythmic drugs are administered.67
9.2.1.3 QRS axis
As VT circuits (especially post-MI or in cardiomyopathies) frequently
lie outside the normal HisPurkinje network, significant axis shifts
are likely to occur, enabling diagnosis. Therefore, in patients with SVT
and aberrancy, the QRS axis is confined between -60 and þ120 . In
particular, extreme axis deviation (axis from -90 to ±180) is strongly
indicative of VT, both in the presence of RBBB and LBBB.65
9.2.1.4 Chest lead concordance
The presence of negative chest lead concordance (all QRS com-
plexes negative V1V6) (Figure 3) is almost diagnostic of VT, with a
specificity >90%, but is only present in 20% of VTs. Positive concord-
ance can be indicative of VT or an antidromic tachycardia utilizing a
left posterior or left lateral AP.68
Table 9 Summary of key electrocardiographic criteria
that suggest ventricular tachycardia rather than supraven-
tricular tachycardia in wide complex tachycardia
AV dissociation Ventricular rate > atrial rate




All precordial chest leads
negative
RS in precordial leads - Absence of RS in precordial leads
- RS >100 ms in any leada
QRS complex in aVR • Initial R wave
• Initial R or Q wave >40 ms
• Presence of a notch of a predomi-
nantly negative complex
QRS axis 290 to 6180 Both in the presence of RBBB and
LBBB morphology
R wave peak time
in lead II
R wave peak time >_50 ms
RBBB morphology Lead V1: Monophasic R, Rsr’, biphasic
qR complex, broad R (>40 ms), and a
double-peaked R wave with the left
peak taller than the right (the so-called
‘rabbit ear’ sign)
Lead V6: R:S ratio <1 (rS, QS patterns)
LBBB morphology Lead V1: Broad R wave, slurred or
notched-down stroke of the S wave,
and delayed nadir of S wave
Lead V6: Q or QS wave
AV = atrioventricular; LBBB = left bundle branch block; RBBB = right bundle
branch block.

















































..9.2.1.5 Right bundle branch block morphology
Lead V1: Typical RBBB aberrancy has a small initial r’, because in
RBBB the high septum is activated primarily from the left septal bun-
dle. Therefore, the following patterns are evident: rSR0, rSr0, or rR0 in
lead V1. However, in VT, the activation wavefront progresses from
the left ventricle (LV) to the right precordial lead V1, in a way that a
prominent R wave (monophasic R, Rsr0, biphasic qR complex, or
broad R >40 ms) will be more commonly seen in lead V1.
Additionally, a double-peaked R wave (M pattern) in lead V1 favours
VT if the left peak is taller than the right peak (the so-called ‘rabbit
ear’ sign). A taller right rabbit ear characterizes the RBBB aberrancy
but does not exclude VT.
Lead V6: A small amount of normal right ventricular voltage is
directed away from lead V6. As this is a small vector in RBBB aber-
rancy, the R:S ratio is >1. In VT, all of the right ventricular voltage, and
some of the left, is directed away from V6, leading to an R:S ratio <1
(rS and QS patterns). An RBBB morphology with an R:S ratio in V6 of
<1 is seen rarely in SVT with aberrancy, mainly when the patient has
a left axis deviation during sinus rhythm.
Differentiating fascicular VT from SVT with bifascicular block
(RBBB and left anterior hemiblock) is very challenging. Features that
indicate SVT in this context include QRS >140 ms, overall negative
QRS in aVR, and an R/S ratio >1 in V6.44
9.2.1.6 Left bundle branch block morphology
Lead V1: As stated above for RBBB, for the same reasons, the
presence of a broad R wave, slurred or notched-down stroke of
the S wave, and delayed nadir of the S wave are strong predictors
of VT.
Lead V6: In true LBBB, no Q wave is present in the lateral precor-
dial leads. Therefore, the presence of any Q or QS wave in lead V6
favours VT, indicating that the activation wavefront is moving away
from the LV apical site.
These morphology criteria are not fulfilled in any lead in 4% of
SVTs and 6% of VTs, and in one-third of cases when one lead (V1 or
V6) favours one diagnosis, the other favours the opposite diagnosis
(VT in one lead and SVT in the other, and vice versa).69,70
A number of algorithms have been developed to differentiate
VT from SVT.69,71,72 Detailed presentation and comments are
beyond the scope of these Guidelines, and can be found in the
2018 European Heart Rhythm Association/Heart Rhythm
Society/Asia Pacific Heart Rhythm Society/Sociedad
Latinoamericana de Estimulacion Cardıaca y Electrofisiologıa
consensus document.3
All of these criteria have limitations. Conditions such as bundle
branch re-entrant tachycardia, fascicular VT, VT with exit site close
to the HisPurkinje system, and wide QRS tachycardia occurring
during antiarrhythmic drug treatment are difficult to diagnose using
the mentioned morphological criteria. Differentiating VT from anti-
dromic AVRT is extremely difficult for the very fact that the QRS
morphology in antidromic AVRT is similar to that of a VT, with its ori-
gin at the insertion of the AP in the ventricular myocardium. An algo-
rithm has been derived for differential diagnosis, based on the analysis
of 267 wide QRS tachycardias, consisting of VT and antidromic










Figure 3 Examples of positive and negative chest lead concordance in VT.









































AVRT. The derived criteria were found to offer sensitivity of 75% and
specificity of 100%,73 and the algorithm was also validated in another
study,74 but experience is still limited.
In fact, several independent studies have found that various ECG-
based methods have specificities of 4080% and accuracies of
75%.44,68,7580 Indeed, a similar diagnostic accuracy of75% would
be achieved effortlessly by considering every wide QRS tachycardia
to be a VT, because only 2530% are SVTs. Therefore, emerging
approaches to integrate these algorithms and provide more accurate
scoring systems are being evaluated.81 Furthermore, conventional
ECG criteria have reduced the sensitivity to distinguish VT from SVT
with aberrancy in patients with idiopathic VT. This is most pro-
nounced in VTs originating from septal sites, particularly Purkinje sites
and the septal outflow tract regions.82
9.2.2 Electrophysiology study
On certain occasions, an EPS is necessary for diagnosis.
9.3 Irregular tachycardias
An irregular ventricular rhythm most commonly indicates AF, multi-
focal AT, or focal AT/atrial flutter with variable AV conduction, and
may occur in the context of both narrow and broad QRS complexes.
When AF is associated with rapid ventricular rates, the irregularity of
this ventricular response is less easily detected and can be misdiag-
nosed as a regular SVT.83 If the atrial rate exceeds the ventricular
rate, then atrial flutter or AT (focal or multifocal) is usually present.
Polymorphic VT and, rarely, monomorphic VT may also be irregular.
Occasionally, a junctional, non-re-entrant tachycardia may have a var-
iable rate.
Specifically, the differential diagnosis of an irregular wide QRS
tachycardia is either pre-excited AF or polymorphic VT, or AT
with variable block in the context of aberrancy. Pre-excited AF
manifests itself by irregularity, a varying QRS morphology, and a
rapid ventricular rate (owing to the short RP of the AP). The
changing QRS morphology results from varying degrees of fusion
due to activation over both the AP and the AVN, which also result
in variation in the width of the delta wave. A further cause of vary-
ing QRS morphology in this context will be if more than one ante-
grade AP is present with intermittent conduction over each. The
ventricular rate tends to be higher than in those with non-pre-
excited AF.84
10 Acute management in the
absence of an established
diagnosis
10.1 Regular tachycardias
10.1.1 Narrow QRS (120 ms) tachycardias
Patients with SVT are common and potentially recurrent attenders
in emergency departments, with an estimated 50 000 visits each
year in the USA.85 The initial approach to acute management tends
to be non-drug-based, with escalation to intravenous (i.v.) drugs
or electrical cardioversion in the absence of early correction
(Figure 4).
10.1.1.1 Haemodynamically unstable patients
Immediate direct-current (DC) cardioversion is the first choice in
haemodynamically compromised patients with narrow QRS
tachycardia.8688,101
10.1.1.2 Haemodynamically stable patients
Vagal manoeuvres can be used to terminate an episode of narrow
QRS SVT.41 The effectiveness of conventional vagal manoeuvres in
terminating SVT, when correctly performed, has been reported as
between 19 and 54%.41,8991,102,103 Vagal manoeuvres include differ-
ent techniques used to stimulate the receptors in the internal carotid
arteries. This stimulation causes a reflex stimulation of the vagus
nerve, which results in the release of acetylcholine, which may in turn
slow the electrical impulse through the AVN and slow the heart rate.
Many of these manoeuvres can be performed with minimal risk at the
bedside or in an office setting, and can be both diagnostic and thera-
peutic. The Valsalva manoeuvre is a safe and internationally recom-
mended first-line emergency treatment for SVT, although a recent
Cochrane review found insufficient evidence to support or refute its
utility.89 The Valsalva manoeuvre has generally been shown to be
most effective in adults, and in AVRT rather than AVNRT. A modified
Recommendations for the acute management of nar-




Synchronized DC cardioversion is recom-




A 12 lead ECG during tachycardia is
recommended.
I C
Vagal manoeuvres, preferably in the supine
position with leg elevation, are
recommended.41,8991
I B
Adenosine (618 mg i.v. bolus) is recom-
mended if vagal manoeuvres fail.9294
I B
Verapamil or diltiazem (i.v.) should be consid-
ered, if vagal manoeuvres and adenosine
fail.92,9498
IIa B
Beta-blockers (i.v. esmolol or metoprolol)
should be considered if vagal manoeuvres and
adenosine fail.97,99,100
IIa C
Synchronized direct-current cardioversion is
recommended when drug therapy fails to con-
vert or control the tachycardia.87,88
I B
i.v. beta-blockers are contraindicated in the presence of decompensated HF.
i.v. verapamil and diltiazem are contraindicated in the presence of hypotension or
HFrEF.
DC = direct current; ECG = electrocardiogram; HF = heart failure; HFrEF =


































































































approach to the Valsalva manoeuvre provides a considerable
enhancement of conversion success rates (43 vs. 17% conversion
rate).41 This enhanced method requires the Valsalva to be completed
semi-recumbent, with supine repositioning and passive leg raise after
the Valsalva strain. Blowing into a 10 mL syringe with sufficient force
to move the plunger may standardize the approach.104 Carotid sinus
massage is performed with the patient’s neck in an extended posi-
tion, with the head turned away from the side to which pressure is
applied. It should always be unilateral as there is a potential risk with
bilateral pressure, and it should be limited to 5 s. The patient should
be monitored. This technique should be avoided in patients with pre-
vious transient ischaemic attack or stroke, and in patients with carotid
bruits.3
Other manoeuvres, such as facial immersion in cold water or
forceful coughing, are rarely used now.
Adenosine, an endogenous purine nucleoside (618 mg i.v. bolus)
is the first drug of choice.9294 Pharmacologically relevant electro-
physiological influences are mediated through cardiac adenosine A1
receptors.105,106 Clinical EPSs have documented progressive dose-
related prolongation of AV conduction [due to effects on the
atrialHis (AH) interval, and none on the HV interval], culminating in
transient AV block that is then responsible for tachycardia
termination.107
The mean dose required for termination is6 mg. To achieve effi-
cient rhythm correction, injection should be as a rapid bolus with
immediate saline flush. Large, centrally located (e.g. antecubital) veins
are likely to deliver more effective drug concentrations to the heart
than smaller distal veins.108 Dosing should then be incremental, start-
ing at 6 mg in adults followed by 12 mg. An 18 mg dose should then
be considered, also taking into account tolerability/side effects in the
individual patient. Adenosine has a very short plasma half-life due to
enzymatic deamination to inactive inosine being achieved in seconds,
with end-organ clinical effects complete within 2030 s.107 Thus,
repeat administration is safe within 1 min of the last dose.2,3 The dose
range between patients may be very wide,107 with >90% success gen-
erally expected.94,109 Some drugs (e.g. dipyridamole and theophyl-
line) may on occasion affect dose requirements, but any influence of
recent intake of caffeinated beverages is disputed.110,111
Transient dyspnoea is common with increased ventilation, and is
more likely to result from the stimulation of pulmonary vagal C
fibres.112 Facial flushing may occur, associated with vasodilatation and
increased skin temperature.107 Chest pain, variable in terms of radia-
tion over the thorax, may suggest ischaemic or oesophageal origins,
and has been associated with increased coronary sinus blood flow so
may well be of cardiac origin.107
Depression of sinoatrial node function is to be expected based on
established pharmacology, but prolonged bradycardia is
unusual.105,107 Nonetheless, adenosine administration should be
approached cautiously in those with known sinus node disease.113
Perceived risks of bradycardia in recipients of denervated orthotropic
heart transplants, in whom SVT is common, have prompted a relative
contraindication.114,115 However, more recent substantive evidence
supports adenosine use in this group with no particular cautions.116
AF may occur following adenosine administration as a result of either
direct pulmonary vein (PV) triggering117 or increasing heterogeneity
of repolarization,118 and appears more commonly associated with
AVRT than AVNRT.93 Adenosine may also occasionally cause or
accelerate pre-excited atrial arrhythmias.119,120
Clinically important bronchoconstriction has been rarely reported
in those receiving i.v. adenosine for SVT,121 and this observation is
further supported by the large experience obtained when adenosine
infusions have been given for cardiac stress testing.105,122,123
Furthermore, despite inhaled adenosine producing bronchoconstric-
tion in people with asthma,124 i.v. administration has had no impact
on the airways in clinical experimental studies.125 There have been
isolated reports of clinically well-documented bronchoconstriction
occurring in patients with or without respiratory disease, thus sug-
gesting that care is required in patients with asthma.121,126,127
However, adenosine can be used cautiously in those with asthma,
although verapamil may be a more appropriate choice in patients
with severe asthma.
Adenosine triphosphate may also be used but clinical experience is
limited.
Calcium channel blockers (verapamil/diltiazem i.v.) and beta-
blockers (e.g. esmolol and metoprolol i.v.) are of value, particularly
in patients with frequent atrial or ventricular premature beats.
Verapamil [0.075 - 0.15 mg/kg i.v. (average 5 - 10 mg) over 2 min] or
i.v. diltiazem [0.25 mg/kg (average 20 mg) over 2 min] has been
shown to terminate SVT in 6498% of patients, but is associated
with a risk of hypotension.92,9498,128 These drugs should be avoided
in patients with haemodynamic instability, HF with reduced LV ejec-
tion fraction (<40%), a suspicion of VT, or pre-excited AF. Beta-
blockers (i.v.), such as short-acting esmolol (0.5 mg/kg i.v. bolus or









































































2.5 mg boluses), are more effective in reducing the tachycardia rate
than in terminating it.97,99,100,128 Although evidence for the effective-
ness of beta-blockers in terminating SVT is limited, they have an
excellent safety profile in haemodynamically stable patients. Beta-
blockers are contraindicated in patients with decompensated HF.
Caution is needed with concomitant use of i.v. calcium channel block-
ers and beta-blockers, because of possible potentiation of hypoten-
sive and bradycardic effects. In the first clinical trial of etripamil, a
short-acting L-type calcium channel blocker with a rapid onset of
action after intranasal administration, conversion rates from SVT to
sinus rhythm ranged from 6595%.129
10.1.2 Wide QRS (120 ms) tachycardias
The acute management of a patient with wide QRS tachycardia
depends on the haemodynamic stability of the patient
(Figure 5).106,130,131
10.1.2.1 Haemodynamically unstable patients
Haemodynamic instability may occur with any wide QRS tachycardia,
regardless of the cause, but is more likely in patients with VT.
Synchronized cardioversion is recommended for any persistent wide
QRS tachycardia resulting in hypotension, acutely altered mental sta-
tus, chest pain, acute HF symptoms, or signs of shock.86,87
10.1.2.2 Haemodynamically stable patients
In a patient with wide QRS tachycardia who is haemodynamically sta-
ble, the response to vagal manoeuvres may provide insight into the
mechanism responsible for the arrhythmia. SVT with aberrancy, if
definitively identified, may be treated in the same manner as narrow
complex SVT, with vagal manoeuvres or drugs (adenosine and other
AVN-blocking agents such as beta-blockers or calcium channel
blockers).117119,129
Some drugs used for the diagnosis or treatment of SVT (e.g. vera-
pamil) can cause severe haemodynamic deterioration in patients with
a previously stable VT.64,133,134 Thus, they should only be used for
the treatment of patients in whom the diagnosis of SVT is fully estab-
lished and secure. Adenosine may be helpful by means of allowing a
diagnosis or interrupting an adenosine-sensitive VT, but it must be
avoided if pre-excitation on resting ECG suggests a pre-excited
tachycardia. There is a risk that in antidromic re-entry, adenosine
may precipitate cardiac arrest if there is induction of AF by adenosine,
as may occasionally occur.135
For pharmacological termination of a haemodynamically stable
wide QRS-complex tachycardia of unknown aetiology, i.v. procaina-
mide or amiodarone can be used in-hospital.132,136138 In the
PROCAMIO trial132 in patients with well-tolerated wide QRS
Recommendations for the acute management of wide




Synchronized DC cardioversion is recommended
in haemodynamically unstable patients.86,130
I B
Haemodynamically stable patients
A 12 lead ECG during tachycardia is
recommended.
I C
Vagal manoeuvres, preferably in the supine
position with leg elevation, are recommended.
I C
Adenosine should be considered if vagal
manoeuvres fail and there is no pre-excitation
on a resting ECG.
IIa C
Procainamide (i.v.) should be considered if
vagal manoeuvres and adenosine fail.132
IIa B
Amiodarone (i.v.) may be considered if vagal
manoeuvres and adenosine fail.132
IIb B
Synchronized DC cardioversion is recom-
mended if drug therapy fails to convert or
control the tachycardia.86,130
I B
Verapamil is not recommended in wide QRS-
complex tachycardia of unknown
aetiology.64,133,134
III B































Figure 5 Acute therapy of wide complex tachycardia in the absence of
an established diagnosis.











































































..tachycardia, with or without reduced LV ejection fraction, procaina-
mide was associated with fewer major cardiac adverse events and a
higher proportion of tachycardia termination within 40 min com-
pared with amiodarone.
In case the mechanism of the arrhythmia is not fully understood,
the arrhythmia should be treated as VT.
10.2 Irregular tachycardias
A wide QRS irregular tachycardia is usually a manifestation of AF.
Rarely, polymorphic VT and, very rarely, monomorphic VT may also
present as irregular tachycardias. Electrical cardioversion is the acute
treatment of choice in irregular pre-excited tachycardias associated
with haemodynamic instability. Specific therapy of pre-excited AF is
discussed in section 11.
If the rhythm is well tolerated with a narrow QRS-complex irregu-
lar tachycardia, this should be considered likely to be AF, and rate
control with beta-blockers or calcium channel blockers, and elective
chemical or electrical cardioversion once thromboprophylaxis is in
place, may be appropriate.4




Sinus tachycardia is defined as a sinus rate >100 b.p.m. On the ECG,
the P wave is positive in leads I, II, and aVF, and biphasic/negative in
lead V1.
11.1.1.1 Physiological sinus tachycardia
The determinants of physiological sinus tachycardia are, by definition,
physiological (effort, stress, or pregnancy), and may also arise secon-
dary to other medical conditions or drugs (Table 10). The 12 lead
ECG shows P-wave morphology typical of normal sinus rhythm.
Physiological sinus tachycardia is treated by identifying and eliminating
the cause.
11.1.1.2 Inappropriate sinus tachycardia
IST is defined as a fast sinus rhythm (>100 b.p.m.) at rest or minimal
activity that is out of proportion with the level of physical, emotional,
pathological, or pharmacological stress.139 The tachycardia tends to
be persistent, and most of the affected patients are young and female,
but this disorder is not limited to that population.140 The underlying
mechanism of IST remains poorly understood and is likely to be mul-
tifactorial (e.g. dysautonomia, neurohormonal dysregulation, and
intrinsic sinus node hyperactivity). Recently, a gain-of-function muta-
tion of the pacemaker hyperpolarization-activated cyclic nucleotide-
gated 4 (HCN4) channel has been reported in a familial form of
IST.141 There is also evolving evidence that immunoglobulin G anti-
beta receptor antibodies are found in IST.142 The prognosis of IST is
generally considered benign140 and the arrhythmia has not been asso-
ciated with tachycardia-induced cardiomyopathy.
11.1.1.2.1 Diagnosis. Patients with IST have a wide spectrum of clinical
presentations ranging from usually asymptomatic or minimally symp-
tomatic palpitations to dyspnoea, exercise intolerance, dizziness, and
light-headedness. The diagnosis of IST is one of exclusion of POTS,
sinus re-entrant tachycardia, or focal AT from the superior part of
the crista terminalis or right superior PV. Characteristically, 24 h
Holter monitoring demonstrates a mean heart rate >90 b.p.m. with
an exaggerated heart rate response >100 b.p.m. during waking
hours.140 Tolerance exercise testing might also be considered to
document the exaggerated heart rate or blood pressure response to
minimal exercise. An EPS is generally not required in making the diag-
nosis, and should not be routinely performed unless, rarely, sinus
node re-entry is suspected.
11.1.1.2.2 Therapy. Reassurance and lifestyle interventions such as
exercise training, volume expansion, and avoidance of cardiac stimu-
lants should be tried before drug treatment (Figure 6).139,143,144 As
the prognosis of IST is benign, treatment is aimed at symptom reduc-
tion and may not be necessary. Beta-blockers have been used in
patients with IST for several years, but may be needed at doses high
enough to cause intolerable side effects such as chronic fatigue. Non-
dihydropyridine calcium channel blockers may also be used, but at
doses that may cause hypotension, and the evidence regarding these
drugs is limited.139,145 Ivabradine, a selective blocker of the ‘pace-
maker current’ (If) in sinoatrial myocytes that directly slow the heart
rate, has been found to be safe and effective in several small tri-
als.146150 However, blockade of the If may perturb the feedback
loop underlying baroreceptor control of autonomic balance, thereby
increasing sympathetic activity to the heart.151 If this effect occurred
chronically at therapeutic dosages, it would be a matter of concern
for its remodelling and pro-arrhythmic potential. Ivabradine should
be preferably co-administered with a beta-blocker when possible;
this combination may also be more beneficial than each drug alone
for IST.152 Ivabradine should not be taken during pregnancy or
Table 10 Causes of physiological sinus tachycardia
Physiological causes Emotion, physical exercise, sexual intercourse, pain, pregnancy
Pathological causes Anxiety, panic attack, anaemia, fever, dehydration, infection, malignancies, hyperthyroidism, hypoglycaemia,
pheochromocytoma, Cushing’s disease, diabetes mellitus with evidence of autonomic dysfunction, pulmonary embolus,
myocardial infarction, pericarditis, valve disease, congestive heart failure, shock
Drugs Epinephrine, norepinephrine, dopamine, dobutamine, atropine, beta-2 adrenergic receptor agonists (salbutamol),
methylxanthines, doxorubicin, daunorubicin, beta-blocker withdrawal


















































breastfeeding.153 As a substrate of cytochrome p450 (CYP) 3A4,
ivabradine should be avoided or used with caution with concomitant
administration of CYP44A inhibitors (ketoconazole, verapamil, diltia-
zem, clarithromycin, and grapefruit juice) or inducers (rifampin and
carbamazepine).154 The limited and disappointing evidence, reported
from small observational studies, suggests that catheter ablation
should not be considered as part of the routine management of most
patients with IST.155161
11.1.1.3 Sinus node re-entrant tachycardia
Sinus node re-entrant tachycardia arises from a re-entry circuit
involving the sinus node and, in contrast to IST, is characterized by
paroxysmal episodes of tachycardia.176 This uncommon arrhythmia
may be associated with paroxysmal symptoms of palpitation, dizzi-
ness, and light-headedness. On the ECG, the polarity and configura-
tion of the P waves are similar to the configuration of sinus
P waves.163
11.1.1.3.1 Diagnosis. The diagnosis of sinus node re-entrant tachycar-
dia is suspected on ECG and Holter ECG. It can be confirmed with
an EPS.
11.1.1.3.2 Therapy. Medical treatment is empirical, and no drugs have
been studied in controlled trials. Verapamil and amiodarone have
demonstrated variable success, whereas beta-blockers are often inef-
fective.163 Sinus node re-entrant tachycardia may be effectively and
safely treated with catheter ablation targeting the site of earliest atrial
activation with respect to the P wave. This approach has been shown
to be feasible with a good long-term outcome.164166
11.1.1.4 Postural orthostatic tachycardia syndrome
POTS is defined as a clinical syndrome usually characterized by an
increase in heart rate of >_30 b.p.m. when standing for >30 s (or >_40
b.p.m. in individuals aged 12 - 19 years) and an absence of orthostatic
hypotension (>20 mmHg drop in systolic blood pressure).177,178
The prevalence of POTS is 0.2% and it represents the most com-
mon cause of orthostatic intolerance in the young,178 with most
patients aged between 15 and 25 years, and >75% being female.
Although the long-term prognosis of POTS has been poorly
explored,50% of patients spontaneously recover within 1 - 3 years.
A number of mechanisms have been described in patients with
POTS, including autonomic nervous system dysfunction,
peripheral autonomic denervation, hypovolaemia, hyperadrenergic
stimulation, diabetic neuropathy, deconditioning, anxiety, and
hypervigilance.178181
11.1.1.4.1 Diagnosis. POTS is diagnosed during a 10 min active stand
test or head-up tilt test with non-invasive haemodynamic
Recommendations for the therapy of sinus tachycardias
Recommendation Classa Levelb
Inappropriate sinus tachycardia
Evaluation and treatment of reversible causes
is recommended.139,144,162
I C
Ivabradine alone or in combination with a
beta-blocker should be considered in sympto-
matic patients.146149,151,152
IIa B
Beta-blockers should be considered in symp-
tomatic patients.139,147
IIa C
Sinus nodal re-entrant tachycardia
Non-dihydropyridine calcium channel block-
ers (verapamil or diltiazem) in the absence of
HFrEF, may be considered in symptomatic
patients.163
IIb C
Catheter ablation should be considered in
symptomatic patients who do not respond to
drug therapy.164166
IIa C
Postural orthostatic tachycardia syndrome
A regular and progressive exercise pro-
gramme should be considered.167169
IIa B
The consumption of >_23 L of water and
1012 g of sodium chloride daily may be
considered.170,171
IIb C
Midodrine, low-dose non-selective beta-
blocker, or pyridostigmine may be
considered.167,170,172174
IIb B
Ivabradine may be considered.175 IIb C
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monitoring. The evaluation of a patient suspected of having POTS
should eliminate other causes of sinus tachycardia such as hypovo-
laemia, anaemia, hyperthyroidism, pulmonary embolus, or pheo-
chromocytoma.178 The clinical history should focus on defining
the chronicity of the condition, possible causes of orthostatic
tachycardia, modifying factors, impact on daily activities, and
potential triggers.
11.1.1.4.2 Therapy. Non-pharmacological treatments should be
attempted first in all patients. These include withdrawing medications
that might worsen POTS, such as norepinephrine transport inhibi-
tors, increasing blood volume with enhanced salt and fluid intake,
reducing venous pooling with compression garments, and limiting
deconditioning. Patients should engage in a regular, graduated, and
supervised exercise programme featuring aerobic reconditioning
with some resistance training for the thighs. Initially, exercise should
be restricted to non-upright exercise, including the use of rowing
machines and swimming, to minimize orthostatic stress on the
heart.180182
If non-pharmacological approaches prove ineffective, pharmaco-
logical therapies may be targeted at specific aspects. Patients strongly
suspected of having hypovolaemia should drink >_23 L of water per
day, and dietary salt intake should be increased to 1012 g/day if
tolerated. Midodrine significantly reduces orthostatic tachycardia but
to a lesser degree than i.v. saline.170 Midodrine has a rapid onset with
only brief effects and is usually administered three times daily. The
drug should only be administered during daytime hours as it can
cause supine hypertension. To reduce unpleasant sinus tachycardia
and palpitations, low-dose propranolol [1020 mg per os (p.o.)]
acutely lowers standing heart rate and improves symptoms in
patients with POTS, while higher doses of propranolol are less well
tolerated.172 Long-acting propranolol does not improve the quality
of life of patients with POTS.167 Non-selective beta-blockers are
preferable because they additionally block epinephrine-mediated
beta-2-vasodilation, but other beta-blockers have not been
adequately studied. Pyridostigmine, a cholinergic agonist that works
by inhibiting acetylcholinesterase, can increase parasympathetic auto-
nomic tone and has a lower risk of hypertension compared with
other medications. Potential side effects include abdominal cramping,
diarrhoea, and muscle cramps.173,174 Ivabradine slows sinus rates
without affecting blood pressure, and in an open-label study60% of
patients with POTS had symptomatic improvement.175 Ivabradine
should ideally be administered with concomitant beta-blockers for
long-term therapy.151
11.1.2 Focal atrial tachycardia
Focal AT is defined as an organized atrial rhythm >_100 b.p.m. initiated
from a discrete origin and spreading over both atria in a centrifugal
pattern. The ventricular rate varies, depending on AV nodal conduc-
tion. In asymptomatic young people (<50 years of age), the preva-
lence of focal AT has been reported to be as low as 0.34% with an
increased prevalence of 0.46% in symptomatic arrhythmia patients.183
Most studies have reported no influence of sex.
Symptoms may include palpitations, shortness of breath, chest
pain, and rarely syncope or presyncope. The arrhythmia may be
sustained or incessant. Dynamic forms with recurrent interruptions
and reinitiations may be frequent.
In patients with PV-related AT, the focus is located at the ostium
of the vein (or within 1 cm of the designated ostium)184 rather than
further distally (24 cm).185
11.1.2.1 Diagnosis
P wave identification from a 12 lead ECG recording during tachycar-
dia is critical (Figure 7). Depending on the AV conduction and AT
rate, the P waves may be hidden in the QRS or T waves. The P waves
are monomorphic with stable CL, which helps to rule out organized
AF. Adenosine injection can help by slowing the ventricular rate or,
less frequently, by terminating focal AT. A discrete P wave with an
intervening isoelectric interval suggests a focal AT. However, distin-
guishing focal from macro-re-entrant arrhythmias by surface ECG is
not always possible. The presence of an isoelectric line does not rule
out a macro-re-entrant mechanism, particularly in the presence of
scar atrial tissue (from structural heart disease or previous extensive
ablation/surgery procedures). In a normal heart and in the absence of
previous ablation, the usual ECG localization rules apply,186 but their
value in localizing the origin of the arrhythmia is also limited in this
context. Focal AT may arise from any site in both atria, but particular
sites of predilection in the normal heart rate are the crista terminalis,
the tricuspid and mitral valve annulus, and within the thoracic veins
joining the atria.46,186 A negative P wave in lead I and aVL suggests an
LA origin. V1 is negative when the arrhythmia source or exit is in the
lateral right atrium, while septal right atrial (RA) and LA origins show
biphasic or positive P waves (Figure 7). Negative P waves in the infe-
rior leads suggest a caudal origin, whereas positive P waves in those
leads favour a superior location.
11.1.2.2 Acute therapy
Hard data for an evidence-based choice of drugs for the acute ther-
apy of focal AT are scarce. In general, acute therapy may be initiated
with beta-blockers or calcium channel blockers, which may terminate
focal ATs or slow the ventricular rate (Figure 8).92,94,187,188
Adenosine (i.v.) may terminate AT [delayed after-depolarizations
(DAD)-triggered AT], but the tachycardia may also continue with AV
block. Class IA, IC, and III drugs may also be effective, by prolonging
refractoriness or suppressing automaticity.189191 Amiodarone may
also be used for cardioversion or slowing of the ventricular rate,192
but the efficacy of rate control is unproven in critically ill patients
with atrial arrhythmias.193 DC cardioversion is usually effective in
acutely terminating the tachycardia, irrespective of the mechanism.
However, in incessant forms of focal AT due to enhanced automatic-
ity, the arrhythmia reinitiates, and repeating DC cardioversion is
unlikely to be appropriate.
11.1.2.3 Catheter ablation
Catheter ablation is the treatment of choice for recurrent focal
AT, especially for incessant AT due to which TCM ensues
(Figure 9).196 Distinguishing macro-re-entrant from focal ATs is
critical for the ablation strategy. Focal ATs, as well as localized/
micro-re-entry ATs, display a centrifugal activation pattern that
spreads throughout the atria. Mapping and ablation of focal ATs is
based on determining the earliest activation site. In PV-related AT,
















Figure 7 Focal atrial tachycardia. (A) Focal atrial tachycardia originating at the lateral right atrium conducted initially with full and then incomplete right
branch bundle block aberration. (B) Focal atrial tachycardia originating at the left atrium (left superior pulmonary vein). (C) Focal atrial tachycardia from the
right atrial appendage. Atrioventricular dissociation during carotid sinus massage (P waves indicated by arrows).




Synchronized DC cardioversion is recommended for haemodynamically unstable patients.8688 I B
Haemodynamically stable patients
Adenosine (618 mg i.v. bolus) should be considered.9294 IIa B
Beta-blockers (i.v. esmolol or metoprolol) should be considered in the absence of decompensated HF, if adenosine fails.187,188 IIa C
Verapamil or diltiazem (i.v.) should be considered for haemodynamically stable patients in the absence of hypotension or HFrEF,
if adenosine fails.92,94
IIa C
If the above measures fail, the following may be used:
• i.v. ibutilide191;
• or i.v. flecainide or propafenone189,190;
• or i.v. amiodarone.192
IIb C
Synchronized DC cardioversion is recommended when drug therapy fails to convert or control the tachycardia.87,88 I B
Chronic therapy
Catheter ablation is recommended for recurrent focal AT, especially if incessant or causing TCM.184,187,194197 I B
Beta-blockers or non-dihydropyridine calcium channel blockers (verapamil or diltiazem in the absence of HFrEF), or propafenone or fle-
cainide in the absence of structural or ischaemic heart disease, should be considered if ablation is not desirable or feasible.188190,198
IIa C
Ivabradine with a beta-blocker may be considered if the above measures fail.199,200 IIb C
Amiodarone may be considered if the above measures fail.201,202 IIb C
i.v. verapamil and diltiazem are contraindicated in the presence of hypotension or HFrEF.
i.v. beta-blockers are contraindicated in the presence of decompensated heart failure.
i.v. ibutilide is contraindicated in patients with prolonged QTc interval.
i.v. flecainide and propafenone are contraindicated in patients with ischaemic or structural heart disease. They also prolong the QTc interval but much less than class III agents.
i.v. amiodarone prolongs the QTc but torsades des pointes is rare.






















..the culprit PV along with other PVs may be preferred. Catheter
ablation is reported to have a 75100% success rate.184,187,194197
Table 11 presents a synopsis of success rates and complications of
catheter ablation for the most common SVTs in the current
era.1113,203208
11.1.2.4 Chronic therapy
Studies addressing chronic therapy are also limited, and thus firm
conclusions cannot be drawn. Beta-blockers and calcium channel
blockers may be effective, and there is a low risk of side effects
(Figure 9).188 Class IC drugs may be effective if first-line therapy has
failed.189,190,198 Ivabradine may also be effective in focal AT,199,200 and
ideally should be given with a beta-blocker. Amiodarone has been
tried in the young and paediatric populations,201,202 and theoretically
should be attractive in patients with impaired LV function. However,






























Figure 8 Acute therapy of focal atrial tachycardia.
































Figure 9 Chronic therapy of focal atrial tachycardia.
AT = atrial tachycardia.
Table 11 Average success and complication rates of catheter ablation for supraventricular tachycardia
Acute success (%) Recurrence (%) Complications (%) Mortality (%)
Focal AT 85 20 1.4a 0.1
Cavotricuspid-dependent atrial flutter 95 10 2b 0.2
AVNRT 97 2 0.3c 0.01
AVRT 92 8 1.5d 0.1
Success rates, recurrence, and complications for focal atrial tachycardia and atrioventricular re-entrant tachycardia vary, being dependent on the location of the focus or path-
way, respectively.1113,203208
aVascular complications, AV block, and pericardial effusion.
bVascular complications, stroke, myocardial infarction, and pericardial effusion.
cVascular complications, AV block, and pericardial effusion.
dVascular complications, AV block, myocardial infarction, pulmonary thromboembolism, and pericardial effusion.

























































11.1.3 Multifocal atrial tachycardia
Multifocal AT is defined as a rapid, irregular rhythm with at least three
distinct morphologies of P waves on the surface ECG. Multifocal AT is
commonly associated with underlying conditions, including pulmonary
disease, pulmonary hypertension, coronary disease, and valvular heart
disease, as well as hypomagnesaemia and theophylline therapy.209 It
may also be seen in healthy infants under 1 year of age, and carries a
good prognosis in the absence of underlying cardiac disease.210
It may be difficult to distinguish multifocal AT from AF on a single
ECG trace, so a 12 lead ECG is indicated to confirm the diagnosis.
On the ECG, the atrial rate is >100 b.p.m. Unlike AF, there is a dis-
tinct isoelectric period between visible P waves. The PP, PR, and RR
intervals are variable. Although it is assumed that the variability of
P-wave morphology implies a multifocal origin, there have been very
few mapping studies of multifocal AT.
11.1.3.1 Therapy
The first-line treatment is management of the underlying condition.
Magnesium (i.v.) may also be helpful in patients, even in those with
normal magnesium levels.211 Antiarrhythmic medications, in general,
are not helpful in suppressing multifocal AT.209 Management often
involves slowing conduction at the AVN level to control heart rate.
Verapamil has some efficacy in patients with multifocal AT who do
not have ventricular dysfunction, sinus node dysfunction, or AV
block.212,213 Metoprolol has been found to be superior to verapa-
mil,214 and beta-blockers can be used with caution to treat multifocal
AT in the absence of respiratory decompensation, sinus node
dysfunction, or AV block. There has also been a case report on the
successful use of ibutilide.215 In symptomatic and medically refractory
cases in which LV deterioration is seen, AV nodal modification may
be used for the control of ventricular rate.216
11.1.4 Macro-re-entrant atrial tachycardias
Atrial flutter and focal AT are traditionally defined according to the
ECG appearance: continuous regular electrical activity, most commonly
a saw-tooth pattern, vs. discrete P waves with an isoelectric line in
between. ECGs with flutter-like appearances are mostly due to macro-
re-entrant atrial circuits but micro-re-entry is also possible. However,
MRATs with a significant part of the activation of the circuit in pro-
tected areas may display a focal AT pattern, with discrete P waves.220
11.1.4.1 Cavotricuspid isthmus-dependent macrore-entrant AT
11.1.4.1.1 Typical atrial flutter: common (counter-clockwise) and
reverse (clockwise). Typical common atrial flutter is the most fre-
quent cavotricuspid isthmus (CTI)-dependent flutter, i.e. a macro-re-
entry circuit around the tricuspid annulus using the CTI as a critical
passage at the inferior boundary. Activation goes downward in the RA
free wall, through the CTI, and ascends in the right septum. Activation
of the LA is passive. The upper part of the circuit may be anterior or
posterior to the superior vena cava. This activation is also known as
counter-clockwise (or anticlockwise) when seen from the apex.
When the circuit is activated in the opposite direction, i.e. clockwise,
it results in a different ECG pattern, then called typical reverse flutter.
11.1.4.1.2 Diagnosis. In counter-clockwise flutter, the circuit results in
regular atrial activation from 250330 b.p.m., with negative saw-
tooth waves in inferior leads and positive waves in V1 (Figure 10). In




Treatment of an underlying condition is rec-
ommended as a first step, if feasible.209
I C
i.v. beta-blockers, or i.v. non-dihydropyridine
calcium channel blockers (verapamil or diltia-
zem) should be considered.213,214
IIa B
Chronic therapy
Oral verapamil or diltiazem should be consid-
ered for patients with recurrent symptomatic
multifocal AT in the absence of HFrEF.217,218
IIa B
A selective beta-blocker should be considered
for patients with recurrent symptomatic multi-
focal AT.214,219
IIa B
AV nodal ablation followed by pacing (prefera-
ble biventricular or His-bundle pacing) should
be considered for patients with LV dysfunction
due to recurrent multifocal AT refractory to
drug therapy.216
IIa C
AT = atrial tachycardia; HF = heart failure; HFrEF = heart failure with reduced
ejection fraction; i.v. = intravenous; LV = left ventricular.
i.v. verapamil and diltiazem are contraindicated in the presence of hypotension or
HFrEF.

















































clockwise flutter, ECG flutter waves in inferior leads look positive
and broad, and are frequently bimodal negative in V1.220,221 Typical
atrial flutter has a strong reproducible anatomical dependence,222
resulting in the morphological reproducibility of the ECG. However,
this well-recognized ECG pattern may be significantly changed when
atrial activation has been modified, as it is in cardiac surgery involving
atrial tissue, after extensive radiofrequency ablation, or in advanced
atrial disease.223,224 Antiarrhythmic drugs may also modify the typical
ECG pattern.225 In these situations, an atypical ECG does not rule
out a circuit of typical flutter using the CTI.226
Typical flutter is related to AF in clinical practice, with both being
associated with similar clinical settings and coexisting in the same
patients: AF may trigger atrial flutter, and after typical flutter ablation
AF is frequent.23,227229 Typical flutter may also frequently occur in
patients treated for AF with class IC drugs or amiodarone. In this
case, flutter rate may be reduced to <200 b.p.m. facilitating 1:1 AV
conduction. The action of antiarrhythmic drugs on ventricular activa-
tion may result in wide QRS tachycardia.230232
Beyond symptoms associated with high-rate and loss of atrial kick,
reversible systolic dysfunction and subsequent TCM are not
unusual.233,234
11.1.4.1.3 Acute therapy. Although the first step should be rate con-
trol when the ventricular rate is high, this may be difficult to achieve.
AV nodal blocking drugs,235238 including amiodarone applied mostly
in HF or critically ill patients,239,240 may be of help, but cardioversion
may be necessary (Figure 11).
In some cases, presenting with 2:1 AV block, the diagnosis of atrial
flutter may not be obvious on the ECG. In these situations, i.v. adeno-
sine may increase the degree of AV block and reveal the typical ECG
pattern. However, adenosine can produce a rebound increase in AV
conduction to 1:1 and may also precipitate AF.271,272 Thus, it should
only be used if deemed necessary for diagnosis and resuscitation
equipment is available.
Rate control should be the first step in very symptomatic patients
with rapid ventricular rates. This is a particularly difficult goal in atrial
Recommendations for the therapy of macro2re-entrant atrial arrhythmias
Recommendations Classa Levelb
Anticoagulation, as in AF, is recommended for patients with atrial flutter and concomitant AF.4 I B





Synchronized DC cardioversion is recommended for haemodynamically unstable patients.248,249 I B
Haemodynamically stable patients
i.v. ibutilide or i.v. or oral (in-hospital) dofetilide are recommended for conversion to sinus rhythm.250257 I B
Low-energy (<_100 J biphasic) electrical cardioversion is recommended for conversion to sinus rhythm.248,249 I B
High-rate atrial pacing is recommended for termination of atrial flutter in the presence of an implanted pacemaker or
defibrillator.258260
I B
i.v. beta-blockers or non-dihydropyridine calcium channel blockers (verapamil or diltiazem) (i.v.), should be considered for control of
rapid ventricular rate.235238
IIa B
Invasive and non-invasive high-rate atrial pacing may be considered for termination of atrial flutter.258,261 IIb B
i.v. amiodarone may be tried if the above are not available or desirable.239,240 IIb C
Propafenone and flecainide are not recommended for conversion to sinus rhythm.250 III B
Chronic therapy
Catheter ablation should be considered after the first episode of symptomatic typical atrial flutter.262,263 IIa B
Catheter ablation is recommended for symptomatic, recurrent episodes of CTI-dependent flutter.262264 I A
Catheter ablation in experienced centres is recommended for symptomatic, recurrent episodes of non-CTI-dependent
flutter.224,265269
I B
Catheter ablation is recommended in patients with persistent atrial flutter or in the presence of depressed LV systolic function due
to TCM.233,234
I B
Beta-blockers or non-dihydropyridine calcium channel blockers (verapamil or diltiazem, in the absence HFrEF) should be considered
if ablation is not desirable or feasible.237,270
IIa C
Amiodarone may be considered to maintain sinus rhythm if the above measures fail.263 IIb C
AV nodal ablation with subsequent pacing (‘ablate and pace’), either biventricular or His-bundle pacing, should be considered if all the
above fail and the patient has symptomatic persistent macro-re-entrant atrial arrhythmias with fast ventricular rates.
IIa C
i.v. verapamil and diltiazem are contraindicated in the presence of hypotension or HFrEF.
i.v. beta-blockers are contraindicated in the presence of decompensated heart failure.
i.v. ibutilide, and i.v. and oral dofertilide are contraindicated in patients with prolonged QTc interval.
i.v. amiodarone prolongs the QTc but torsades des pointes is rare.
AF = atrial fibrillation; AV = atrioventricular; CTI = cavotricuspid isthmus; DC = direct current; HFrEF = heart failure with reduced ejection fraction; i.v. = intravenous; LV = left


























































Figure 11 Acute therapy of stable atrial flutter or macro-re-entrant atrial tachycardia.




























































































..flutter and even the combination of AVN-blocking drugs (digoxin,
beta-blockers, and calcium channel blockers)235238 may fail, mak-
ing cardioversion to sinus rhythm necessary. Dofetilide and ibuti-
lide, pure class III antiarrhythmic drugs, are generally effective in
interrupting atrial flutter in i.v. administration (dofetilide may be
also given orally for this purpose), while class IA and IC drugs have
little or no effect.250257 Class IC antiarrhythmic drugs should not
be used in the absence of AV-blocking agents because of the risk
of slowing the atrial rate, which may result in 1:1 AV conduc-
tion.273,274 Amiodarone may not be very effective acutely to re-
establish sinus rhythm, but it does help to control the ventricular
rate if it is too fast.275,276 Low-energy electrical cardioversion is
commonly used with haemodynamic compromise or after failure
of previous actions, but it could be the first choice due to its high
efficacy. Electrical cardioversion for atrial flutter is more effective
and less energy is required, compared with AF.248,249 When atrial
electrodes are in place, high-rate stimulation can be used to con-
vert flutter, sometimes through AF.258,259 If pacing induces AF,
this may allow better control of the ventricular rate than flutter.
Atrial stimulation can also be done with percutaneous endocardial
electrodes or from the oesophagus; this is mostly done in paediat-
rics.261 Pre-treatment with procainamide may facilitate conver-
sion of atrial flutter by atrial pacing.277 Data on pre-cardioversion
anticoagulation are lacking, but most probably patients should be
treated the same as those with AF.4,278
11.1.4.1.4 Catheter ablation. Catheter ablation is the most effective
therapy to maintain sinus rhythm, and is clearly superior to amio-
darone.262,263 Ablation of CTI with confirmed bidirectional con-
duction block results in a <10% rate of recurrence.279 However,
the incidence of AF is high in the long-term.280 When typical CTI-
dependent atrial flutter ensues during antiarrhythmic drug therapy
(class IC or amiodarone) for AF, CTI ablation is a reasonable
choice to ensure that antiarrhythmic drugs can be continued for
AF control.262,263
Although no procedure-related mortality had been detected in
early studies,203,204 in recent studies, mortality and stroke rates of
0.2 - 0.34 and 0.19 - 0.5%, respectively, have been reported
(Table 11).12,206 In a recent registry, ablation for flutter had a higher
mortality than that for AF (0.3 vs. 0.05%), but this might have been
due to the comorbidities or advanced ages of patients referred for
flutter ablation.207
11.1.4.1.5 Chronic therapy. Rate control is part of the therapeutic
approach, using AV nodal blocking agents such as diltiazem, verapamil,
or beta-blockers (Figure 12). When ablation is not feasible or the
patient’s preference, antiarrhythmic drugs may also be used to maintain
sinus rhythm. Dofetilide257 and sotalol281 are useful, but there are con-
cerns about pro-arrhythmia. Amiodarone may have a role,263 but it
should be restricted to cases of HF or significant structural heart disease.
11.1.4.1.6 Anticoagulation. Data about the embolic risk of atrial
flutter have usually been derived in the presence of concomitant
AF, thus making individualized risk stratification difficult. Left
atrial (LA) appendage ‘stunning’ and thrombi seem to be lower
compared with those in AF.247,282 The thrombo-embolic risk of
atrial flutter, although lower than that of AF,246 is still signifi-
cant.241244 That, together with the association with AF, justifies
thromboprophylaxis, and anticoagulation has been recom-
mended as in AF.2,3 These recommendations extend to the acute
setting for cardioversion when flutter lasts for >48 h.278
However, it should be noted that there is a lack of prospective,
dedicated, randomized studies on the subject. Furthermore, the
value of the CHA2DS2-VASc [Cardiac failure, Hypertension, Age
>_75 (Doubled), Diabetes, Stroke (Doubled)  Vascular disease,
Age 6574 and Sex category (Female)] score in preventing
ischaemic stroke in patients with atrial flutter has not been estab-
lished,245 and in patients without concomitant AF the threshold
for the initiation of anticoagulation appears to be higher than that
for patients with AF.246
11.1.4.1.7 Other cavotricuspid isthmus-dependent macrore-
entrant atrial tachycardia. An atypical ECG pattern may not
exclude CTI-dependent MRAT.283 Lower-loop re-entry refers to a
circuit rotating around the inferior vena cava instead of around the
tricuspid annulus. It may be clockwise or counter-clockwise.284,285
When rotating counter-clockwise, it might be considered a variant of
typical counter-clockwise flutter with a caudal shift of the cranial
turning point posterior to the entry of the superior vena cava, result-
ing in a similar ECG appearance. ‘Figure-of-eight double-loop re-
entry’ may also occur around the inferior vena cava and tricuspid
annulus, and mimic typical clockwise atrial flutter.285 Other circuits
using part of the CTI or even restricted inside it, are in essence CTI-
dependent with a similar ECG appearance to typical common
flutter.286,287
11.1.4.2 Non-cavotricuspid isthmus-dependent macrore-entrant atrial
tachycardia
The terms non-CTI-dependent MRAT and atypical flutter are
used interchangeably, and describe flutter waves in the ECG not
suggestive of typical circuits. The pitfall with this use comes from
the atypical ECG that may happen when typical circuits develop in
diseased atria, most frequently after surgery or extensive ablation,
or under the effects of antiarrhythmic drugs. Conversely, upper-
loop re-entry may mimic a typical flutter ECG pattern without
being CTI-dependent.283 True atypical flutter is actually a post hoc
diagnosis when the circuit has been outlined and dependence on
CTI has been ruled out.
11.1.4.2.1 Right atrium macro2re-entrant atrial tachycardia. Atrial
sutures and patches used for complex congenital heart disease sur-
gery, together with progressive atrial damage, create multiple
obstacles and protected isthmuses that constitute the substrate for
complex and multiple MRAT.288,289 This usually happens around RA
free wall scars. However, in patients with complex congenital heart
disease, the presence of extensive atrial scars hinders the differential
diagnosis of focal or MRAT.290
Figure-of-eight double-loop tachycardias mimicking the ECG pat-













































RA MRAT may also occur in the absence of previous interven-
tion. Most of these are sustained around areas of ‘electrical
silence’ in the RA free wall, probably due to fibrosis.224,264,266
Atypical atrial flutter could also arise from upper loop re-entry in
the right atrium with conduction through the gap in the crista
terminalis.269
Rate control is often difficult due to the regularity and usually
slow rate of the tachycardia. Antiarrhythmic drugs are often inef-
fective, or their use is limited because of structural heart disease
and comorbidities. Radiofrequency ablation of often several crit-
ical isthmuses is the most effective treatment. Circuits around
scars of longitudinal atriotomy can be mapped and ablated with
good long-term results.267,292 However, owing to the complexity
of possible substrates and difficulty of reaching critical isthmuses,
ablation procedures for these patients should be restricted to
experienced operators and centres.
11.1.4.2.2 Left atrium macro2re-entrant atrial tachycardia. Circuits
sustaining LA atypical flutter/MRAT are most usually due to electri-
cally silent areas of abnormal tissue, following medical interventions
or progressive atrial degeneration/fibrosis.268 Anatomical obstacles
such as the ostia of PVs, and mitral annulus, are often involved.
Owing to its widespread use, AF ablation is the procedure that fre-
quently causes the lesions able to sustain re-entry circuits, usually after
linear ablation or extensive defragmentation. Pre-existing atrial disease
is also predictive of macro-re-entry.293 Localized segmental PV dis-
connection may cause focal tachycardias,294 and circumferential antral
ablation may also create MRAT due to gaps in the lines.295299 AT
due to a small re-entrant circuit after ablation of AF may possibly be
distinguished from macro-re-entry by a shorter P-wave duration. RA
MRATs have a higher incidence of negative polarity in at least one pre-
cordial lead compared with LA macro-re-entry.300302
Atrial circuits are also created after surgery for different condi-
tions, including mitral valve disease, and are related to incisions or
cannulation.303 Surgery to treat AF may also result in macro-re-entry
circuits and focal AT.304
Circuits causing atypical left MRAT may also occur in the LA with-
out prior intervention, commonly, but not invariably, associated with
significant left heart disease.305 These are based on areas of electrical
silence, probably due to fibrosis, engaging anatomical obstacles such
as the ostia of the PVs or the mitral annulus, and may be ablated by
interrupting critical isthmuses.265,306 Circuits may also happen in the




































Figure 12 Chronic therapy of atrial flutter/macro-re-entrant atrial tachycardia.













































..Peri-mitral flutter, sometimes incorporating silent areas at the
roof of the LA, is ablated in a similar way to peri-tricuspid circuits.
However, the deployment of a stable line of block at critical isth-
muses is more challenging.308310 Circuits around the PVs are
also frequently recognized and ablated.280,295,296 Intervention to
treat these tachycardias after the initial procedure should be
delayed, if possible, for >_3 months. As part of the maturation
process of the deployed lesions, some tachycardias may be transi-
ent in nature,311 and initial rate control and/or use of antiarrhyth-
mic drugs is favoured.
11.2 Atrioventricular junctional
arrhythmias
11.2.1 Atrioventricular nodal re-entrant tachycardia
AVNRT denotes re-entry in the area of the AVN, but the exact cir-
cuit remains elusive. The AVN is a three-dimensional structure with
greater variability in the space constant of tissue, and poor gap junc-
tion connectivity due to differential expression of connexin isoforms,
conditions that provide an explanation for dual conduction and nodal
re-entrant arrhythmogenesis.312314 There has also been consider-
able histological and electrophysiological evidence that the right and
left inferior extensions of the human AVN, and the atrionodal inputs
that they facilitate, may provide the anatomical substrate for the slow
pathway.315,316 Thus, comprehensive models of the tachycardia
circuit for all forms of AVNRT based on the concept of atrionodal
inputs have been proposed.47,317
Onset of AVNRT seems to occur bimodally over time. In
many patients, attacks indeed manifest early in life, whereas in a sub-
stantial proportion of patients AVNRT starts later, e.g. in the
fourth or fifth decade of life.318 One-half of the patients with minimal
symptoms and short-lived, infrequent episodes of tachycardia may
become asymptomatic within the next 13 years.319 AVNRT may
result in AF that usually, although not invariably, is eliminated follow-
ing catheter ablation of AVNRT.320 Familial AVNRT should be
considered.321
11.2.1.1 Diagnosis
11.2.1.1.1 12 lead electrocardiogram during tachycardia. Typically,
AVNRT is a narrow complex tachycardia, i.e. QRS duration <120 ms,
unless there is aberrant conduction, which is usually of the RBBB type,
or a previous conduction defect exists (Figure 13). AV dissociation is
exceptionally uncommon, but it can occur as neither the atria nor the
ventricles are necessary for the re-entry circuit. Thus, coexistence with
AF or AV conduction block is possible but rare.66,322 ST-segment
depression may be seen during or after the tachycardia.
In the typical form of AVNRT (also called slowfast AVNRT),





















Figure 13 Atrioventricular nodal re-entrant tachycardia. (A) Typical atrioventricular nodal re-entrant tachycardia. (B) Atypical atrioventricular nodal re-























































majority of cases, are indiscernible or very close to the QRS com-
plex. Thus, P waves are either masked by the QRS complex or
seen as a small terminal P’ wave that is not present during sinus
rhythm.323
In the atypical form of AVNRT, P waves are clearly visible before
the QRS, i.e. RP>PR, denoting a long RP tachycardia, and are negative
or shallow in leads II, III, aVF, and V6, but positive in V1.317
Tachycardia-related ST-segment depression, RR-interval varia-
tion, as well as QRS alternans may be seen. Specific, although
modestly sensitive, ECG criteria for AVNRT, as opposed to AT
and AVRT, are a pseudo R deflection in lead V1 and a pseudo S
wave in the inferior leads, a notch in lead aVL, and a pseudo R in
aVR.45 If the tachycardia is initiated by atrial ectopic beats, the ini-
tial (ectopic) P wave usually differs from the subsequent (retro-
grade) P waves.
11.2.1.1.2 Electrophysiology study. Heterogeneity of both fast and
slow conduction patterns has been well described, and all forms of
AVNRT may display anterior, posterior, and middle, or even LA ret-
rograde, activation patterns.322324 Thus, specific electrophysiologi-
cal manoeuvres may be required for differential diagnosis of typical
and, especially, atypical AVNRT from focal AT or AVRT due to a
concealed septal pathway.45 The rare form of verapamil-sensitive AT
is due to re-entry in the atrial tissue close to the AVN, but not the
AV nodal conducting system.325
11.2.1.1.3 Typical atrioventricular nodal re-entrant tachycardia. In
the slowfast form of AVNRT, the onset of atrial activation appears
before, at the onset of, or just after the QRS complex, thus maintain-
ing an AH/Hisatrial (HA) ratio >1. The VA interval measured from
the onset of ventricular activation on surface ECG to the earliest
deflection of the atrial activation in the His bundle electrogram is <_60
ms. Although, the earliest retrograde atrial activation is typically
recorded at the His bundle electrogram, careful mapping studies
have demonstrated that posterior or even left septal fast pathways
may occur in <_7.6% in patients with typical AVNRT.326328
11.2.1.1.4 Atypical atrioventricular nodal re-entrant tachycardia.
Atypical AVNRT is seen in 6% of all AVNRT cases,317 and in some
patients may coexist with the typical form.329 A higher incidence of
atypical AVNRT has been documented in athletes.330 In the so-
called ‘fastslow form of AVNRT, retrograde atrial electrograms
begin well after ventricular activation with an AH/HA ratio <1,
indicating that retrograde conduction is slower than antegrade
conduction. The AH interval is <185200 ms. The VA interval
measured from the onset of ventricular activation on surface ECG
to the earliest deflection of the atrial activation in the His bundle
electrogram is >60 ms. Earliest retrograde atrial activation has gen-
erally been reported at the base of the triangle of Koch, near the
coronary sinus ostium, but it can be variable, with eccentric atrial
activation at the lower septum or even the distal coronary
sinus.328,331,332 In the ‘slowslow’ form, the AH/HA ratio is >1
and the AH interval >200 ms, but the VA interval is >60 ms, sug-
gesting that two slow pathways are utilized for both anterograde
and retrograde activation. Earliest retrograde atrial activation is
usually at the coronary sinus ostium, but variants of left-sided atrial
retrograde activation have also been published.333,334 The distinc-
tion between ‘fastslow’ and ‘slowslow’ forms is of no practical
significance, and certain cases of atypical AVNRT cannot be classi-
fied according to described criteria.324 There is also evidence that
the ‘fast’ pathway during slowfast AVNRT is not identical to the
‘fast’ component of so-called fastslow AVNRT.329 Therefore,
AVNRT can be classified as typical or atypical according to the HA
interval, or—when a His bundle electrogram is not reliably
recorded—according to the VA interval measured on the His bun-
dle recording electrode.322 Table 12 presents a conventional classi-
fication system. Other approaches have also been published.335
11.2.1.2 Therapy
Table 12 Classification of atrioventricular nodal re-
entrant tachycardia types324
HA VA (His) AH/HA
Typical AVNRT <_70 ms <_60 ms >1
Atypical AVNRT >70 ms >60 ms Variable
Atypical atrioventricular nodal re-entrant tachycardia has been traditionally classi-
fied as fastslow (Hisatrial >70 ms, ventriculoatrial >60, atrialHis/Hisatrial
<1, and atrialHis <200 ms) or slowslow (Hisatrial >70 ms, ventriculoatrial
interval >60 ms, atrialHis/Hisatrial >1, and atrialHis >200 ms). Intermediate,
unclassified types may also exist. AH = atrialHis interval; AVNRT = atrioven-
tricular nodal re-entrant tachycardia; HA = Hisatrial interval; VA = ventriculoa-
trial interval measured from the onset of ventricular activation on surface ECG to
the earliest deflection of the atrial activation on the His bundle electrogram.
Recommendations for the management of atrioventric-




Synchronized DC cardioversion is recommended
for haemodynamically unstable patients.8688
I B
Haemodynamically stable patients
Vagal manoeuvres, preferably in the supine posi-
tion with leg elevation, are recommended.41,8991
I B
Adenosine (618 mg i.v. bolus) is recommended
if vagal manoeuvres fail.9294
I B
Verapamil or diltiazem i.v. should be considered if
vagal manoeuvres and adenosine fail.92,9498
IIa B
Beta-blockers (i.v. esmolol or metoprolol) should
be considered if vagal manoeuvres and adenosine
fail.97,99,100
IIa C
Synchronized DC cardioversion is recommended



































































































11.2.1.2.1 Acute therapy. Most data on the effectiveness of vagal
manoeuvres and adenosine for acute termination of tachycardia
are derived from mixed populations of SVT, as described in section
10.1.1 on the acute therapy of SVT in general, but it seems that
they are less successful in AVNRT than in AVRT.89,90,102 A single
dose of oral diltiazem (120 mg) plus a beta-blocker (i.e. proprano-
lol 80 mg) may convert <_94% of patients, but there is a risk of
hypotension, transient AV block, or—rarely—syncope.342,343
Caution is needed in the elderly, and in patients with known sinus
or AV nodal conduction disturbances. A single dose of oral flecai-
nide (3 mg/kg) may also be effective, albeit at a lower rate.342,344
Intranasal etripamil is promising (see section 10.1.1).129 Rarely,
when vagal manoeuvres and adenosine cannot terminate the
tachycardia and hypotension ensues, synchronized DC cardiover-
sion is indicated101 (Figure 14).
11.2.1.2.2 Catheter ablation. A recent randomized clinical trial
(RCT) that compared catheter ablation as first-line treatment with
antiarrhythmic drugs demonstrated significant benefits in arrhythmia-
related hospitalizations.336 Furthermore, catheter ablation for SVT in
general, and AVNRT in particular, is the current treatment of choice
for symptomatic patients because it substantially improves quality of
life28,345,346 and reduces costs.347349 Slow-pathway modification is
effective in both typical and atypical AVNRT.338 Usually, a combined
anatomical and mapping approach is employed, with ablation lesions
delivered at the inferior part of the triangle of Koch, either from the
right or the left septal side.337339,350,351 This approach offers a suc-
cess rate of 97%, has an 1.34% recurrence rate, and has been
associated with a risk of AV block of <1% in previous
reports.203,204,352,353 Recent experience indicates that in experienced
centres, the procedure can be accomplished in both typical and atypi-
cal AVNRT with almost no risk of AV block, by targeting the inferior
nodal extension and avoiding the mid-septum, and the roof of the
coronary sinus.208,338,354,355 Success rates are lower (82%) and the
risk of heart block higher (14%) in patients with adult congenital heart
disease (ACHD).356 Usually, recurrences are seen within 3 months
following a successful procedure in symptomatic patients who expe-
rience frequent episodes of tachycardia,317,329,336,338 but in the young,
aged <_18 years, recurrences may be seen as long as 5 years
post-ablation.357 IST may occur, but is usually transient and not
frequent following slow-pathway ablation.358 Advanced age is not a
contraindication for slow-pathway ablation.359 The pre-existence
of first-degree heart block carries a higher risk for late AV block
and avoidance of extensive slow pathway ablation is preferable
under such conditions.360 There is almost no procedure-related
mortality.11,13,203205,208 Cryoablation may carry a lower risk of AV
block, but is associated with a significantly higher recurrence
rate.361363 Its favourable safety profile and higher long-term success
rate in younger patients make it especially attractive for the treat-
ment of children.364 AVNRT is a cause of inappropriate shocks
in patients with implantable cardioverter defibrillators (ICDs) and,
in the case of frequent episodes, catheter ablation is clearly
indicated.365
11.2.1.2.3 Chronic therapy. Patients with minimal symptoms and
short-lived, infrequent episodes of tachycardia can be followed-up
without the need for ablation or long-term pharmacological ther-
apy (Figure 15). Approximately one-half of them may become
asymptomatic within the next 13 years.319 Chronic administration
of antiarrhythmic drugs decreases the frequency and duration of
Chronic therapy
Catheter ablation is recommended for sympto-
matic, recurrent AVNRT.208,336339
I B
Diltiazem or verapamil, in patients without HFrEF,
or beta-blockers should be considered if ablation
is not desirable or feasible.340342
IIa B
Abstinence from therapy should be considered
for minimally symptomatic patients with very
infrequent, short-lived episodes of tachycardia.319
IIa C
i.v. verapamil and diltiazem are contraindicated in the presence of hypotension or
HFrEF.
i.v. beta-blockers are contraindicated in the presence of decompensated heart
failure.
DC = direct-current; HF = heart failure; HFrEF = heart failure with reduced ejec-





































Figure 14 Acute therapy of atrioventricular nodal re-entrant
tachycardia.

































































































AVNRT, but has a variable success rate in abolishing tachycardia
episodes, ranging from 13 - 82%, and <_20% of patients may discon-
tinue therapy.323 In view of the excellent success rate and minimal
risk of catheter ablation in symptomatic cases, the value of long-
term antiarrhythmic drug therapy seems very limited.
11.2.2 Non-re-entrant junctional tachycardias
Junctional ectopic tachycardia (JET), or focal junctional tachy-
cardia, is an uncommon arrhythmia that arises from abnormal
automaticity at the AVN or proximal His bundle. Focal junctional
tachycardia in children may be seen as a congenital arrhythmia or,
more often, early after infant open-heart surgery.366,367
Congenital junctional tachycardia carries considerable morbidity
and mortality.368 Junctional tachycardia can also be seen in adult
patients with a structurally normal heart,369,370 and has in the past
been associated with non-fibrinolysed acute MI.371 The usual ECG
finding in JET is a narrow QRS tachycardia with a short RP interval
or AV dissociation. Occasionally, the tachycardia might be irregu-
lar and resemble AF.
Propranolol (i.v.) with or without procainamide,370 verapamil,
or procainamide,372 or flecainide,373 may be used for acute ther-
apy, but data are scarce. Amiodarone (i.v.) is the drug of choice
for post-operative JET as well as for preventing early JET in chil-
dren after open-heart surgery.374,375 In children with congenital
junctional tachycardia, amiodarone alone, or with propafenone
or ivabradine, appears effective.368,376379 For chronic therapy,
propranolol370 or, in the absence of ischaemic or structural
heart disease, flecainide380 and propafenone,381 may be tried.
Selective catheter ablation at the site of the earliest retrograde
atrial activation is feasible, but carries a lower success rate and
higher AV block risk compared with AVNRT (5 - 10%).369,382
Cryoablation is safer.375,383
Non-paroxysmal junctional tachycardia was frequently diag-
nosed in the past as a junctional rhythm of gradual onset and ter-
mination, with a rate between 70130 b.p.m., and was considered
a typical example of digitalis-induced DADs and triggered activity
in the AVN.3 The RP interval during tachycardia is variable.
Myocardial ischaemia, hypokalaemia, chronic obstructive pulmo-
nary disease, and myocarditis are also associated conditions.
Non-re-entrant AV nodal tachycardia caused by simultane-
ous multiple nodal pathway conduction (often called
double-fire pathology or dual AV nodal tachycardia) is an
uncommon mechanism of AV nodal tachycardia,384,385 and has
been associated with repetitive retrograde concealment or
‘linking’ phenomena.386388 These are expressed in the form
of ventricular pauses with consistent AV relationship after the
pause, and can often be misdiagnosed as AF.389 These extremely
rare tachycardias may cause TCM and respond to slow-pathway
ablation.
11.3 Atrioventricular arrhythmias
AVRTs use an anatomically defined re-entrant circuit that consists of
two limbs: first, the AVNHPS, and second, an AP also called the
bypass tract. The two limbs are characterized by differences in refrac-
toriness and conduction times, with critically timed premature atrial
or ventricular beats initiating re-entrant tachycardia. On rare occa-
sions, the circuit consists of two APs.
11.3.1 Accessory pathways
APs are single or multiple strands of myocardial cells that bypass
the physiological conduction system, and directly connect atrial
and ventricular myocardium.390 These AV connections are due to
incomplete embryological development of the AV annuli, without
complete separation of the atria and ventricles. While there are
different types of APs, the most common are those that connect
the atrium and the ventricle along the mitral or tricuspid annulus.
Approximately 60% are located along the mitral valve and are
referred to as left free wall APs, 25% insert along the septal aspect
of the mitral or tricuspid annulus, and 15% insert along the right
free wall.391393 Because ventricular muscle is lacking in the prox-
imity of the anterior leaflet of the mitral valve, left-sided APs are
usually limited to the region of the mitral annulus at the attach-
ment of the mural (posterior) leaflet. APs located in the supero-
paraseptal area in close proximity to the His bundle and AVN may
also occur.394
APs present characteristic electrophysiological features that differ
from AV nodal conduction properties. They typically exhibit fast con-
duction (with the exception of atypical pathways-see section 11.3.9),
dependent on a sodium current similar to that of myocardial cells.
Moreover, although a majority of APs conduct both antegradely and
retrogradely, some propagate impulses in only one direction. Those

























Figure 15 Chronic therapy of atrioventricular nodal re-entrant tachy-
cardia.











































whereas those that conduct in the retrograde direction only are
more frequent (<_50%). When the AP conducts antegradely, ventric-
ular pre-excitation is usually evident at rest during sinus rhythm and
the AP is referred to as ‘manifest’. Conversely, APs are referred to as
‘concealed’ if they exclusively conduct retrogradely. Concealed APs
may have decremental properties.395 The term ‘latent AP’ denotes
an AP that is not, or is barely, visible due to location or faster conduc-
tion through the AVN.
Multiple APs occur in <_12% of patients with pre-excitation, and in
<_50% in patients with Ebstein’s anomaly.396
AVRT is the most common tachycardia associated with APs. Two
mechanisms of re-entry are possible according to the antegrade or
retrograde conduction over the AVNHPS, and are classified as
orthodromic and antidromic AVRT.
11.3.2 WolffParkinsonWhite syndrome
WPW syndrome refers to the presence of an overt (manifest) AP,
thus resulting in the so-called pre-excitation, in combination with
usually recurrent tachyarrhythmias.397 During sinus rhythm, a typ-
ical pattern in the resting ECG with the following characteristics is
present: (i) a short PR interval (<_120 ms); (ii) slurred upstroke (or
downstroke) of the QRS complex (‘delta wave’); and (iii) a wide
QRS complex (>120 ms). In most cases, APs giving rise to the
WPW pattern are seen in structurally normal hearts. Rare, familial
forms of pre-excitation associated with LV hypertrophy and multi-
system disease [mutations in the protein kinase adenosine
monophosphate-activated non-catalytic subunit gamma 2
(PRKAG2) gene, Danon and Fabry disease, and others] have also
been described.398
Several surface ECG algorithms have been developed that can be
applied for the localization of APs in the presence of overt pre-
excitation (Figures 16 and 17).399401 Pre-excitation on the surface
ECG can be intermittent and can even disappear permanently (in
<_35% of cases) over time. Furthermore, various degrees of pre-
excitation are possible depending on the location of the AP as well as
on AVN conduction properties.
11.3.3 Orthodromic atrioventricular re-entrant
tachycardia
Orthodromic AVRT accounts for >90% of AVRTs and for
20 - 30% of all sustained SVTs. The re-entrant impulse conducts
from the atrium to the ventricle through the AVNHPS, which is
the anterograde limb of the re-entrant circuit, whereas the AP
conducts from the ventricle to the atrium, and serves as the
Figure 16 The St George’s algorithm for the localization of accessory pathways.399þve = QRS complex-positive;ve = QRS complex-negative;þ/- =
QRS complex equiphasic; AP = accessory pathway; LAL = left anterolateral; LP = left posterior; LPL = left posterolateral; LPS = left posteroseptal; MS =












































..retrograde limb of the re-entrant circuit. Orthodromic
AVRT tends to be a rapid tachycardia, with frequencies
ranging from 150 to, rarely, >220 b.p.m. During tachycardia
(Figure 18), the following ECG features can be present: (i) RP
interval constant and, usually but not invariably, up to one-half of
the tachycardia CL; (ii) narrow QRS; (iii) functional BBB usually
associated with an AP ipsilateral to the blocked bundle, especially
in young patients (aged <40 years); and (iv) ST-segment
depression.
11.3.4 Antidromic atrioventricular re-entrant tachycardia
Antidromic AVRT occurs in 3 - 8% of patients with WPW syn-
drome.402404 The re-entrant impulse travels from the atrium to
the ventricle through the AP with anterograde conduction; mean-
while, retrograde conduction occurs over the AVN or another
AP, usually located in a contralateral position to ensure longer
travel distances, thus allowing for sufficient recovery of refractori-
ness of the respective elements of the re-entrant circuit. In
30 - 60% of patients with spontaneous antidromic AVRT, multiple
APs (manifest or concealed), which could act or not as the retro-
grade limb during the AVRT, may be detected. Antidromic AVRT
has the following ECG features, illustrated in Figure 18: (i) a wide
QRS complex (fully pre-excited) and (ii) an RP interval that is
difficult to assess as the retrograde P wave is usually inscribed
within the ST-T segment.
11.3.5 Accessory pathway as a bystander
In the presence of focal AT, atrial flutter, AF, or AVNRT, the QRS
complexes can be pre-excited when the AP acts as a bystander, and
is not a critical part of the re-entry circuit.
11.3.6 Pre-excited atrial fibrillation
Paroxysmal AF has been found in 50% of patients with WPW, and
may be the presenting arrhythmia in affected patients.405,406
These patients are typically young and have no structural heart
disease. High-rate AVRT may potentially initiate AF. AF with
fast ventricular response over an overt AP with a short anterog-
rade refractory period is a potentially life-threatening arrhythmia
in patients with WPW syndrome, due to potential degeneration
into VF.
11.3.7 Concealed accessory pathways
Concealed APs give rise only to orthodromic AVRT. Their true prev-
alence is unknown because they are not detectable on the resting
surface ECG, but only at occurrence of AVRT, or during electro-
physiology testing.45 No sex predilection is found and these pathways
Figure 17 Localization of accessory pathways in the presence of maximum (spontaneous or evoked) pre-excitation.400 Accessory pathway locations
are green when right-sided and red when left-sided. Left posterolateral accessory pathways can have 0, 1, or 2 inferior leads with positive polarity, whereas
nodo-Hisian accessory pathways can have 1, 2, or 3 inferior leads with positive polarity. Right-sided accessory pathways are framed orange or yellow when
the V3 lead is negative or positive, respectively. Left posterior accessory pathways are framed blue when the V1/I ratio is <1 or purple when V1/I ratio is
>_1. AP = accessory pathway; DCS = deep coronary sinus; LL = left lateral; LPL = left posterolateral; LPS = left paraseptal; NH = nodo-Hisian; RA = right














































tend to occur more frequently in younger patients than in those with
AVNRT; however, significant overlap exists.3 Concealed APs are pre-
dominantly localized along the left free wall (64%), and less frequently
at septal (31%) and right free wall locations.395 Clinical presentation
is with AVRT. Concealed pathways are not associated with an
increased risk of sudden cardiac death. The management of AVRT
due to a concealed AP is similar to that of an overt AP, but in this
case is related to symptoms without significant prognostic relevance
in most cases.
11.3.8 Permanent junctional reciprocating tachycardia
PJRT is a rare form of AV reciprocating tachycardia using a concealed
AP. Usually these APs, originally described by Coumel, are located in
the posteroseptal region and are associated with retrograde decre-
mental conduction properties.407 PJRT is a long RP tachycardia due
to the slow conduction properties of the AP, and is characterized by
deeply inverted retrograde P waves in leads II, III, and aVF due to the
retrograde nature of atrial activation. The incessant nature of PJRT
may result in TCM that usually resolves after successful treatment by
radiofrequency catheter ablation, particularly in younger
patients.407,408 Catheter ablation is strongly recommended in symp-
tomatic patients or in cases with impaired LV ejection fraction likely
related to TCM.
Other potential causes of long RP tachycardias are sinus tachycar-
dia, AT, atypical AVRT, and JET with 1:1 retrograde conduction.
11.3.9 Atypical forms of pre-excitation
Other APs are postulated to result in cardiac pre-excitation. Atypical
APs (also called Mahaim fibers) are connections between the right
atrium or the AVN and the right ventricle, into or close to the right
bundle branch.409414 Most of them are atriofascicular or nodoven-
tricular (as initially described), but they can also be atriofascicular,
atrioventricular, nodofascicular, or nodoventricular, depending on
their variable proximal and distal insertions.413,414 Left-sided atypical
pathways have also been described but are extremely rare.415417
Atypical pathways usually contain accessory nodal tissue, which
results in decremental properties, and connect the atrium to the fas-
cicles by crossing the lateral aspect of the tricuspid annulus, but post-
eroseptal locations can also be found in rare cases. Conduction is
usually anterograde only, but concealed fibres have also been
described.412,418 The following properties define the behaviour of
atypical pathways:
• Baseline normal QRS or different degrees of manifest pre-
excitation with LBBB morphology;
• Programmed atrial pacing, leading to obvious manifest pre-
excitation following an increase in AV interval along with short-































Figure 18 Atrioventricular re-entrant tachycardia. Left: othodromic atrioventricular re-entrant tachycardia due to a concealed posteroseptal accessory
pathway. Retrograde P waves are negative during tachycardia in the inferior leads (arrows). Right: Antidromic atrioventricular re-entrant tachycardia due
to an atriofascicular accessory pathway. The axis during tachycardia due to atypical pathways depends on the way of insertion into the right bundle and










































• Antidromic AVRT due to an atriofascicular pathway usually pro-
duces a horizontal or superior QRS axis, but a normal axis may
also occur, depending on the way of insertion into the right bun-
dle and fusion over the left anterior fascicle.
• Right bundle electrogram preceding His bundle activation during
anterograde pre-excitation and SVT.
Mapping identifies the proximal and distal insertion of accessory
fibres, and demonstrates pathway potentials in most cases that then
guide ablation.409,411 Catheter ablation is associated with a high suc-
cess rate and low recurrence rates, and is therefore recommended
for all patients with recurrent symptomatic tachycardia, and espe-
cially incessant tachycardias due to concealed nodofascicular or
nodoventricular pathways.418 Preventive ablation for prognostic rea-
sons is not routinely recommended, not even in patients with pre-
excitation or BBB in the surface ECG, as fast conduction via the AP is
unlikely due to decremental conduction properties.
11.3.10 Therapy
11.3.10.1 Acute therapy
Adenosine should be used with caution for the treatment of AVRT
because of potential induction of fast AF.119,120,272 AF with fast ventricular
conduction could also induce ventricular fibrillation, therefore electrical
cardioversion should always be available. During orthodromic and anti-
dromic AVRT, drug therapy could be directed at one of the components
of the circuit, the AVN (beta-blockers, diltiazem, verapamil, or etripa-
mil),100,129,419,420 or the AP (ibutilide, procainamide, propafenone, or fle-
cainide)421,422 (Figure 19). Antidromic AVRT is associated with malignant
WPW syndrome due to a very fast-conducting AP,403 and drugs acting
mainly on the AP should be preferred. In addition, in case of antidromic
AVRT with APs representing both the anterograde and retrograde limb,
drugs acting on the AVN are ineffective. In drug-refractory antidromic
AVRT, amiodarone may also be considered.423425
In patients presenting with pre-excited AF, urgent cardioversion is
usually required and the threshold for the use of electrical cardiover-
sion is lower. Conduction of electrical impulses can occur preferen-
tially via the AP due to its shorter RP compared with the AVN.426
Accordingly, any AVN-modulating agents (adenosine, verapamil, dil-
tiazem, beta-blockers, or digoxin) should be avoided in pre-excited
AF as they may contribute to a risk of ventricular fibrillation.427,428
Pharmacological cardioversion of pre-excited AF or delayed AP con-
duction can be achieved with ibutilide (Figure 20).421 Drugs such as
procainamide, propafenone, or flecainide, which affect conduction





Synchronized DC cardioversion is recommended for haemodynamically unstable patients.8688 I B
Haemodynamically stable patients
Vagal manoeuvres, preferably in the supine position with leg elevation, are recommended.41,8991 I B
In orthodromic AVRT, adenosine (618 mg i.v. bolus) is recommended if vagal manoeuvres fail and the tachycardia is
orthodromic.9294
I B
In orthodromic AVRT, i.v. verapamil or diltiazem should be considered if vagal manoeuvres and adenosine fail.92,9498 IIa B
In orthodromic AVRT, i.v. beta-blockers (esmolol or metoprolol) should be considered in the absence of decompensated HF, if
vagal manoeuvres and adenosine fail.97,99,100
IIa C
In antidromic AVRT, i.v. ibutilide or procainamide or i.v. flecainide or profanenone or synchronized DC cardioversion should be
considered if vagal manoeuvres and adenosine fail.421,422,429,437
IIa B
In antidromic AVRT, i.v. amiodarone may be considered in refractory cases.423425,435 IIb B
Synchronized DC cardioversion is recommended when drug therapy fails to convert or control the tachycardia.87,88 I B
Chronic therapy
Catheter ablation of AP(s) is recommended in patients with symptomatic, recurrent AVRT.391393,438441 I B
Beta-blockers or non-dihydropyridine calcium-channel blockers (verapamil or diltiazem in the absence of HFrEF) should be consid-
ered if no signs of pre-excitation are present on resting ECG, if ablation is not desirable or feasible.340,341,442,443
IIa B
Propafenone or flecainide may be considered in patients with AVRT and without ischaemic or structural heart disease, if ablation
is not desirable or feasible.429,444,445
IIb B
Digoxin, beta-blockers, diltiazem, verapamil, and amiodarone are not recommended and are potentially harmful in patients with
pre-excited AF.427,428,432434,446
III B
i.v. verapamil and diltiazem are contraindicated in the presence of hypotension or HFrEF.
i.v. beta-blockers are contraindicated in the presence of decompensated heart failure.
i.v. ibutilide is contraindicated in patients with prolonged QTc interval.
i.v. procainamide prolongs the QTc interval but much less than class III agents.
i.v. flecainide and propafenone are contraindicated in patients with ischaemic or structural heart disease. They also prolong the QTc interval but much less than class III agents.
i.v. amiodarone prolongs the QTc but torsades des pointes is rare.
AF = atrial fibrillation; AP = accessory pathway; AVRT = atrioventricular re-entrant tachycardia; DC = direct-current; ECG = electrocardiogram; HFrEF = heart failure with
























or i.v. propafenone or flecainide


























Figure 19 Acute therapy of atrioventricular re-entrant tachycardia.
AVRT = atrioventricular re-entrant tachycardia; i.v. = intravenous.
Recommendations for the acute therapy of pre-excited atrial fibrillation
Recommendation Classa Levelb
Haemodynamically unstable patients
Synchronized DC cardioversion is recommended in haemodynamically unstable patients.86,130 I B
Haemodynamically stable patients
Ibutilide or procainamide (i.v.) should be considered.421,430,436 IIa B
Flecainide or propafenone (i.v.) may be considered.429,431 IIb B
Synchronized DC cardioversion is recommended if drug therapy fails to convert or control the tachycardia.86,130 I B
Amiodarone (i.v.) is not recommended.432435 III B
i.v. ibutilide is contraindicated in patients with prolonged QTc interval.
i.v. procainamide prolongs the QTc interval but much less than class III agents.
i.v. flecainide and propafenone are contraindicated in patients with ischaemic or structural heart disease. They also prolong the QTc interval but much less than class III agents.
























































over the AP, may also be used, even if they may not restore sinus
rhythm.429431 However, class Ic drugs should be used with caution
as they do exert an effect on the AVN. In pre-excited AF, i.v. amio-
darone may not be as safe as previously thought, because enhanced
pathway conduction and ventricular fibrillation have been reported,
and should not be considered.432435 Procainamide appears to be
safer in this setting.436
11.3.10.2 Catheter ablation
The treatment of choice for patients with symptomatic and recur-
rent AVRT, or pre-excited AF, is catheter ablation (Figure 21). For
other patients with asymptomatic and infrequent episodes, thera-
peutic decisions should be balanced between the overall risks and
benefits of the invasive nature of ablation vs. long-term commit-
ment to pharmacological therapy. Ablation of the AP has a high
acute success rate and is associated with a low complication rate
depending on the pathway location (Table 9).391393,438440 Major
complications include cardiac tamponade (0.131.1%) and com-
plete AV block (0.172.7%) in patients in whom ablation of septal
APs is attempted. With septal APs close to the AVN, the ECG typ-
ically displays a positive delta wave in leads avF and avL, and a nar-
row positive delta wave in lead V1 that has a prominently negative
QRS complex.394
When targeting septal pathways and applying cryoenergy, the inci-
dence of AV block is lower compared with radiofrequency energy.447
However, recurrence of previously blocked pathways has been
reported to be significantly higher when cryoenergy is applied.438
Two approaches are available for left-sided pathways: an antegrade
transseptal and a retrograde aortic approach. There is evidence that
the transseptal approach, in experienced hands, results in reduced
radiation and procedure times.441,448
The 2015 American College of Cardiology/American Heart
Association/Heart Rhythm Society Guideline for the Management
of Adult Patients With Supraventricular Tachycardia reported
major complication rates after radiofrequency catheter ablation
of 3.0 and 2.8% for AVNRT and AVRT, respectively.2 These rates
are much higher than those reported by experienced electro-
physiologists in the current era, as summarized in Table 9, but the
procedure still carries a very small, non-negligible, mortality
risk.203,205
11.3.10.3 Chronic therapy
If ablation is not desirable or feasible in patients with pre-
excitation and symptomatic antidromic AVRT, and in whom struc-
tural or ischaemic heart disease has been excluded, class IC antiar-
rhythmic drugs act mainly on the AP and can be used in
antidromic tachycardia (Figure 21).429,437,444,445 In cases of pre-
excited AF, caution should be taken not to transform it into atrial
flutter and induce 1:1 conduction. Apart from class IC drugs, beta-
blockers, diltiazem, or verapamil may also be considered in case of
orthodromic tachycardias if no signs of pre-excitation are
observed on the resting ECG.340,341,442,443
11.3.11 The asymptomatic patient with pre-excitation
Most patients with an asymptomatic WPW pattern will go
through life without any clinical events related to their ventricular
pre-excitation. Approximately one in five patients will develop an
arrhythmia related to their AP during follow-up. The most com-
mon arrhythmia in patients with WPW syndrome is AVRT (80%),
































Figure 21 Chronic therapy of atrioventricular re-entrant tachycardia.





















Figure 20 Acute therapy of pre-excited atrial fibrillation.
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secondary to pre-excited AF that conducts rapidly to the ventricle
over the AP, resulting in ventricular fibrillation, is the most feared
manifestation of WPW syndrome. The risk of cardiac arrest/ven-
tricular fibrillation has been estimated at 2.4 per 1000 person-
years (95% confidence interval 1.33.9), but no deaths were
reported in a registry of 2169 patients over an 8 year follow-up
period.439 However, in a Danish registry of 310 individuals with
pre-excitation (age range 885 years), there was a greater risk of
AF and HF, driven by a right anteroseptal AP, and in patients aged
>65 years there was also a statistically significant higher risk of
death.22
Clinical and electrophysiological features associated with an
increased risk of sudden cardiac death include younger
age,439,449,450 inducibility of AV-reciprocating tachycardia during
EPS,450454 multiple APs,450,451,455,456 and demonstration of a
capability of the AP to allow rapid conduction to the ven-
tricles.439,450,451,453456 These variables include the shortest pre-
excited RR interval during AF (SPERRI) of <_250 ms at baseline or
a short antegrade effective refractory period (ERP) of the AP
(<_250 ms).439,450452,454460 With non-invasive testing, identifica-
tion of an abrupt and complete normalization of the PR interval
with loss of delta wave during exercise testing, or following pro-
cainamide, propafenone, or dispopyramide administration, has
been considered a marker of low risk.459,461463 Catecholamine
sensitivity is a major limiting factor of all tests, both invasive452,460
and non-invasive, including exercise testing.459,461,462 Intermittent
loss of pre-excitation on a resting ECG or ambulatory monitoring
has also been associated with APs with longer ERPs, and has been
accepted as a credible risk-stratification tool.2,464 However, a
number of recent studies, which have included both symptomatic
and asymptomatic patients, have indicated that more than one-
fifth of patients with intermittent pre-excitation have AP ERPs
<250 ms. Thus, intermittent pre-excitation is now recognized as
an imperfect marker of a low-risk AP.406,462,465469
Over the past 30 years, a considerable body of literature has
been published that has focused on the important topic of the
evaluation and management of patients with asymptomatic pre-
excitation. These publications include those that describe the clin-
ical and electrophysiological characteristics of patients with pre-
excitation who have experienced a cardiac arrest,439,451,455,459
and series of patients with pre-excitation who are either sympto-
matic or asymptomatic, and are followed for variable periods of
time.22,405,439,449,450,454,456,470472 Among these studies, there has
been one prospective RCT of catheter ablation (37 patients) vs.
clinical follow-up without treatment (35 patients) of patients with
asymptomatic pre-excitation.453 Catheter ablation reduced the
frequency of arrhythmic events (7 vs. 77%, P < 0.001) over 5 years.
One patient in the control group had an episode of cardioverted
ventricular fibrillation.
Figure 22 summarizes the recommendations for the screening and
management of patients with asymptomatic pre-excitation.
Recommendations for the management of patients with
asymptomatic pre-excitation
Recommendation Classa Levelb
Performance of an EPS, with the use of isopre-
naline, is recommended to risk stratify individ-
uals with asymptomatic pre-excitation who
have high-risk occupations/hobbies,c and those
who participate in competitive
athletics.439,450452,454460
I B
Catheter ablation is recommended in asymp-
tomatic patients in whom electrophysiology
testing with the use of isoprenaline identifies
high-risk properties, such as SPERRI <_250 ms,
AP ERP <_250 ms, multiple APs, and an induci-
ble AP-mediated tachycardia.439,450,452,454460
I B
Catheter ablation is recommended in high-risk
patients with asymptomatic pre-excitation
after discussing the risks, especially of heart
block associated with ablation of anteroseptal
or MS APs, and benefits of the
procedure.439,440,473476
I C
Performance of an EPS to risk stratify individu-
als with asymptomatic pre-excitation should
be considered.439,450452,454460
IIa B
Non-invasive evaluation of the conducting
properties of the AP in individuals with asymp-
tomatic pre-excitation may be
considered.459,461463,465469
IIb B
Invasive risk stratification with an EPS is rec-
ommended in patients without ‘low-risk’ char-
acteristics at non-invasive risk
stratification.462,463,465469,477
I C
Clinical follow-up should be considered in a
patient with asymptomatic pre-excitation and
a low-risk AP at invasive risk
stratification.450,452,456,463,477
IIa C
Catheter ablation may be considered in a
patient with asymptomatic pre-excitation, and
a low-risk AP at invasive or non-invasive risk
stratification.405,450,452,456,463,477
IIb C
Catheter ablation should be considered in
patients with asymptomatic pre-excitation and
LV dysfunction due to electrical
dyssynchrony.478481
IIa C
Catheter ablation may be considered in
patients with low-risk asymptomatic pre-exci-




AP = accessory pathway; EPS = electrophysiology study; ERP = effective refrac-
tory period; LV = left ventricular; MS = mid-septal; SPERRI = shortest pre-excited
RR interval during atrial fibrillation.
aClass of recommendation.
bLevel of evidence





















..Invasive screening with an EPS should be performed in patients
with asymptomatic pre-excitation who either have high-risk occupa-
tions or are competitive athletes (Figure 22). Variables on the EPS
that identify patients with a high-risk AP include a SPERRI <_250 ms,
AP ERP <_250 ms, multiple APs, and an inducible AP-mediated tachy-
cardia in the baseline state or during isoproterenol infusion, which
should always be tried.452,460 The options for screening patients who
do not fall into these groups include the use of EPS as a risk-stratifying
tool or the use of non-invasive screening with exercise testing, drug
testing, and ambulatory monitoring as risk-stratification tools.
If a patient undergoes screening with an EPS and is found to have
an AP with ‘high-risk’ characteristics, catheter ablation should be per-
formed. Catheter ablation of an AP, when performed by an experi-
enced operator, is associated with a high cure rate (>95%) and low
risk (<0.5%) of major complications (see also Section

































Figure 22 Risk stratification and therapy of patients with asymptomatic pre-excitation. High-risk features at electrophysiology study are shortest pre-
excited RR interval during atrial fibrillation <_250 ms, accessory pathway effective refractory period <_250 ms, multiple accessory pathways, and inducible
atrioventricular re-entrant tachycardia. Low-risk features at non-invasive risk stratification are induced or intermittent loss of pre-excitation on exercise or
drug testing, resting electrocardiogram, and ambulatory electrocardiogram monitoring.
























































































..studies do not confer absolute certainty about risk assessment. In a
recent retrospective study in 912 young patients (aged <_21 years)
with WPW syndrome, 96 experienced life-threatening events,405 of
whom 49% had rapidly conducted pre-excited AF. In patients with
events subjected to EPS risk stratification, 22 of 60 (37%) did not
have EPS-determined high-risk characteristics, and 15 of 60 (25%)
had neither concerning pathway characteristics nor inducible AVRT.
There has also been evidence supporting the notion of LV dysfunc-
tion related to electrical asynchrony in patients, especially children,
with asymptomatic pre-excitation.478481 It seems reasonable to rec-
ommend EPS and consider ablation if a link between pre-excitation
and LV dysfunction can be made.
Catheter ablation of an asymptomatic ‘low-risk’ AP also appears
reasonable in appropriately experienced centres according to
informed patient choice. However, when a decision is made to per-
form catheter ablation, it is important to recognise that ablation of
APs in the anteroseptal or mid-septal (MS) region is associated with a
small risk of AV block. The risk of heart block associated with ablation
of anteroseptal or MS APs may preclude ablation of an anteroseptal
or MS AP in an asymptomatic patient.
Thus, the approach for patients with asymptomatic pre-excitation
that does not exhibit high-risk characteristics at EPS depends on the
experience and expertise of the electrophysiologist performing the
procedure, as well as the preferences and values of the patient. In the
CASPED registry involving 182 children and adolescents with asymp-
tomatic pre-excitation, catheter ablation achieved a 91% success rate
without significant complications.482
12 Supraventricular tachycardia in
adults with congenital heart
disease
The number of adults with congenital heart disease is increasing at a
rate of 60% per decade in developed countries.483,484 Currently, it
is estimated that 1 million adults with congenital heart disease live
in the European Union. Despite ongoing advances in paediatric sur-
gery and cardiology, allowing >90% of children born with congenital
heart disease to survive to adulthood,485 these patients usually con-
tinue to be afflicted by late complications leading to increased mor-
bidity and mortality. Alongside HF, cardiac arrhythmias are a
common late complication in adults with congenital heart defects.486
This is due to the underlying cardiac defect, previous or persisting
haemodynamic issues, and previous surgical interventions resulting in
myocardial damage and scarring.487 Arrhythmic burden ranges from
bradycardia arrhythmias to SVTs, and life-threatening VTs or
fibrillation.
Owing to preceding operations and underlying anatomy, patients
with tetralogy of Fallot, Ebstein’s anomaly, transposition of the great
arteries after atrial switch procedure, and complex patients with uni-
ventricular hearts and Fontan palliation are especially prone to late
development of arrhythmias, such as incisional or intra-atrial re-entry
tachycardia, and ventricular tachycardia.488 However, even patients
with usually non-complex lesions such as atrial septal defects have an
increased life risk of atrial arrhythmias.
In addition to being related to symptoms, SVTs have been
reported as risk factors for sudden cardiac death in patients with
ACHD. This issue particularly affects patients with obstructive lesions
of the systemic ventricle, tetralogy of Fallot, after Fontan operation,
and a systemic right ventricle.489,490 Unfortunately, diagnosis and
treatment of arrhythmias in ACHD patients is complicated by the
unusual nature of tachycardia, complex intracardiac anatomy, and
especially by difficulties in accessing the heart, for example due to
abnormal venous anatomy (e.g. azygos continuity or previous Fontan
operation). As a consequence, specific expertise in patients with
ACHD and access to adequate electrophysiological tools are




Acute therapy of SVT in the context of ACHD is as described for
narrow QRS SVT, in general.491,492 Randomized controlled trials of
chronic antiarrhythmic therapy in patients with complex ACHD are
lacking. All antiarrhythmic drugs carry a proarrhythmic risk, and many
patients with ACHD have underlying sinus node dysfunction or a
predisposition for AVN disease. Antiarrhythmic drugs should there-
fore be used with particular caution, and are generally reserved for
symptomatic patients after options for catheter ablation procedures
and haemodynamic optimization (e.g. correction of underlying valvu-
lar problems) have been exhausted. Beta-blockers may be used to
slow AV nodal conduction and may be considered, with caution, in
patients with transposition of the great arteries after the atrial switch
operation. This is supported by studies reporting a reduction in ven-
tricular fibrillation and/or appropriate ICD shocks in patients treated
with beta-blocking drugs.493,494 However, care is needed as these
patients may suffer from chronotropic incompetence and cannot tol-
erate beta-blockade.495 Owing to recognized pro-arrhythmic effects,
class IC drugs should be used with appropriate caution in the ACHD
setting. Similar considerations refer to quinidine, disopyramide, and
sotalol. In the recent report of the DARE study cohort, amiodarone,
flecainide, and sotalol were clearly found to be pro-arrhythmic, espe-
cially in the presence of a prolonged QT, in older women, and in
patients with underlying cardiovascular comorbidity, family history of
sudden death, and hypokalaemia.496 Flecainide is highly effective in
infants with SVT, but there are concerns about its toxicity at older
ages.496,497 Most centres have a lower threshold for the use of
amiodarone in patients with ACHD as it is perceived to be less pro-
arrhythmic. However, it is commonly associated with thyroid disor-
ders and less commonly with other well-described potentially
life-changing complications. These considerations should severely
limit its long-term use in patients with ACHD, thus further support-
















































..12.2 Catheter and surgical ablation
Owing to underlying anatomy and previous operations, interventional
access for ablation procedures may be challenging in patients with
ACHD. In addition, the nature of SVT is often atypical, and related to
multiple re-entrant circuits and fibrotic atrial tissue. As a consequence,
special expertise and experience with ablation of complex tachyarrhyth-
mias and scar-related procedures are necessary.506 It is recommended
that patients with complex incisional tachycardias are referred to spe-
cialist centres with adequate experience, volumes of ablation proce-
dures, and advanced mapping capabilities. Catheter ablation procedures
in the setting of ACHD are associated with lower success rates com-
pared with the general cohort of patients with AF or atrial flutter.484
However, ablation of CTI-related arrhythmias has been reported to
have a high acute success rate (>95%), although the mid-term recur-
rence rate may approach 20%.507 Pre-operative catheter ablation or
concomitant arrhythmia surgery should be considered in patients with
ACHD undergoing cardiac surgery, as its incorporation can result in
improved functional class and potentially decreased requirements for
chronic antiarrhythmic medication in this vulnerable population.502504
12.3 Specific disease states
12.3.1 Atrial septal defect
The incidence of atrial arrhythmias in patients with atrial septal defects
ranges between 515%.508 The exact impact of atrial septal defect clo-
sure, especially of late closure, on the risk of developing AT is contro-
versial. Patients commonly present with RA MRAT. The leading
mechanism is CTI-dependent tachycardia and this is generally suscepti-
ble to catheter ablation. However, CTI-dependent and ‘incisional’ atrial
flutter may coexist. Closure of an existing atrial septal defect, in isola-
tion, is generally insufficient to abolish an existing AT and catheter abla-
tion should be considered before defect closure. Mid-term recurrence
rates of 4044% have been reported in atrial septal defect patients
post-flutter or AF ablation508,509; however, this should not preclude
ablation procedures wherever possible.
12.3.2 Ebstein’s anomaly
ATs are common in Ebstein’s anomaly, occurring in 2565% of
patients.501,510512 The types of arrhythmia include atrial flutter, focal AT,
and AF. In addition, 1045% of patients have right-sided APs, including
WPW syndrome. More than one AP is common in this setting, and can in
itself increase the risk of haemodynamic compromise and sudden cardiac
death. Catheter ablation of APs has a high success rate; however, ablation
procedures may be challenging and repeat procedures may be necessary
as some patients have multiple ablation targets. In addition, patients may
develop different arrhythmia mechanisms following ablation.501 In patients
undergoing surgical repair, routine pre-operative EPS can be recom-
mended as the diagnostic and therapeutic yield in this population is high.513
12.3.3 Transposition of the great arteries (dextro-
transposition of the great arteries) after atrial switch
operation (Mustard or Senning)
Owing to previous surgery and scarring, atrial re-entrant tachycardias
are common in patients with a Mustard or Senning repair. In addition,
Recommendations for the therapy of supraventricular tachycardia in congenital heart disease in adults
Recommendation Classa Levelb
Anticoagulation for focal AT or atrial flutter should be similar to that for patients with AF.241,242,499 I C
Acute therapy
Haemodynamically unstable patients
Synchronized DC cardioversion is recommended for haemodynamically unstable patients.8688,491,492 I B
Haemodynamically stable patients
Vagal manoeuvres, preferably in the supine position with leg elevation, are recommended.41,8991 I B
Adenosine (618 mg i.v. bolus) is recommended if vagal manoeuvres fail.9294 I B
i.v. verapamil or diltiazem should be considered, if vagal manoeuvres and adenosine fail.92,9498 IIa B
i.v. beta-blockers esmolol or metoprolol) should be considered if vagal manoeuvres and adenosine fail.97,99,100 IIa C
Synchronized DC cardioversion is recommended when drug therapy fails to convert or control the tachycardia.87,88 I B
Chronic therapy
Catheter ablation in experienced centres should be considered.292,500,501 IIa C
Beta-blockers should be considered for recurrent focal AT or atrial flutter, if ablation is not possible or successful.237 IIa C
In patients with SVT planned for surgical repair of a congenital heart disease anomaly, pre-operative catheter ablation or intraopera-
tive surgical ablation should be considered.502504
IIa C
Amiodarone may be considered for prevention if ablation is not possible or successful.505 IIb C
Sotalol is not recommended as a first-line antiarrhythmic drug as it is related to an increased risk of pro-arrhythmias and mortality.496 III C
Flecainide and propafenone are not recommended as first-line antiarrhythmic drugs in patients with ventricular dysfunction and
severe fibrosis.497
III C
i.v. verapamil and diltiazem are contraindicated in the presence of hypotension or HFrEF.
i.v. beta-blockers are contraindicated in the presence of decompensated heart failure.



































































































sinus node dysfunction may occur as a consequence of the atrial redi-
rection procedure.495 As tachycardia is not well tolerated in patients
with asystemic right ventricular and diastolic dysfunction, maintaining
long-term sinus rhythm is highly desirable in this setting. Use of antiar-
rhythmic drugs is limited due to ventricular and sinus node dysfunction,
and pro-arrhythmic risk. Ablation procedures in patients with a
Mustard or Senning repair have a high acute success rate; however,
recurrence rates approach 30% during long-term follow-up.500,514516
12.3.4 Tetralogy of Fallot
SVTs are not uncommon in patients with tetralogy of Fallot. In addition to
being related to symptoms, the occurrence of supraventricular arrhyth-
mias has been linked to a statistically higher risk of sudden cardiac death in
this population.517 As catheter ablation has a high procedural success rate,
it should be considered as a first-line option in this setting.518 In addition,
patients with new-onset atrial arrhythmias should be thoroughly eval-
uated to exclude addressable haemodynamic lesions such as severe pul-
monary valve regurgitation, which may be amenable to surgical or
interventional therapy leading indirectly to reduced arrhythmia burden.
12.3.5 Fontan repairs
AT is common in patients post-Fontan palliation. Patients with a classic
(atriopulmonary) Fontan procedure are at especially high risk for AT,
with <_60% developing SVTs after 15 years of follow-up.519 In addition to
symptoms and the risk of cardiac thromboembolism, AT is poorly toler-
ated haemodynamically in patients with univentricular hearts, and may
lead to acute deterioration and overt HF in this setting.520 Catheter abla-
tion is often effective but challenging, due to the nature of the arrhythmia
circuits as well as issues with cardiac access.514,515 Various surgical modi-
fications, such as the conversion to total cavopulmonary connection,
have evolved and can ameliorate the risk of atrial arrhythmias.521
13 Supraventricular tachycardia in
the paediatric population
Specific detailed recommendations for paediatric patients are pub-
lished elsewhere522,523 and are beyond the scope of this document.
In general, certain aspects are different in the paediatric population
and should be taken into account.
Immaturity of the cardiac structures, including conduction tissue,
may lead to modifications in the electrophysiology of the heart.
Therefore, some APs present in the first months of life (even those
associated with tachycardias) may disappear before the first year of
age.522 Actually, AVRT due to WPW that begins in infancy may
resolve in 90% of patients, but may recur in later childhood in
30 - 50% of patients; however, if the tachycardia is present after the
age of 5, it persists in >75% of patients.524
It is clear that small children may not complain of symptoms, so
indirect signs have to be assessed when SVT is suspected, i.e. irritabil-
ity, failure to thrive, and even flat growing curves. It is not uncommon
to discover an incessant SVT in a patient presenting with cardiogenic
shock due to TCM. This most frequently occurs in relatively slow
SVTs, such as PJRT and focal AT.525,526
Pharmacokinetics and pharmacodynamics in children are different
to those in adults; therefore, special attention has to be given when
prescribing drugs.527 This is particularly important in newborns as
milk can substantially modify the absorption of the drug and, as feed-
ing schedules tend to be erratic, can affect effective drug availability.
Furthermore, many drugs have to be prepared at specialized pharma-
cies, adding to the risk of incorrect dosing, and drug solutions may
also need to be stored under special conditions to maintain their
stability. This can be inconvenient when long-term treatment is
required as, for example, a portable cooler bag must be carried. In
addition, the long-term effects of some drugs, as they accumulate, are
especially dangerous in growing bodies. This is of special interest
regarding amiodarone, which can chronically provoke the same sec-
ondary effects as it does in adults. Verapamil has to be avoided when-
ever possible or given very carefully to small patients as it can
provoke severe hypotension.522 A decreased response of adenosine
in younger children has also been suggested.528
Invasive techniques are possible and effective even in very small
children, when indicated, but there are several limiting factors. First,
radiofrequency lesion formation in immature sheep myocardium is
similar to that in adult sheep myocardium acutely, but is associated
with late lesion enlargement and fibrous tissue invasion of normal
myocardium. These observations may have implications for clinical
radiofrequency ablation procedures in infants529 and avoidance of
radiofrequency ablation, if at all possible, in the first 2 years of life is
prudent. Second, no specific catheters and tools exist for the paediat-
ric population. Currently, available catheters (minimum 5 French for
non-irrigated radiofrequency tips) and curves are, in general, too
large. This is particularly limiting in small children needing an ablation
to resolve incessant tachycardia. Finally, the experience of the opera-
tor and the centre is crucial. Small patients requiring ablation should
be referred to experienced reference centres for treatment. The
number of catheters used, and procedural and radiation times, should
be minimized in these growing bodies.530 Electroanatomical mapping
systems are most valuable in this setting.
13.1 Foetal arrhythmias
Foetal arrhythmias can be detected at an early gestational age, with
incessant, rapid SVTs associated with foetal death due to hydrops.
Therefore, a special effort has to be made to detect and control foetal
arrhythmias. A strong correlation between post-natal SVT and later ges-
tational age at foetal SVT diagnosis has been reported.531 Diagnosis
relies on echocardiography as foetal ECGs are not available in most clin-
ics (it is used in just a few centres worldwide and primarily for research
purposes).532 When sustained foetal tachycardia is observed, treatment
is mandated. There are several protocols for this purpose, and they are
mostly based on digoxin, flecainide, and sotalol alone or in combination
depending on the type of tachycardia. These drugs have to be given to
the mother, with a fraction reaching the foetus. This means that the sec-
ondary effects of these drugs can manifest in both the foetus and
mother. Close follow-up is therefore needed.522,533,534
14 Supraventricular tachycardia in
pregnancy
Sustained SVT becomes more frequent during pregnancy, occurring
in 2224/100 000 pregnancies. It may even manifest for the first
time, particularly in the third trimester or peri-partum, according to





















































.frequency of any arrhythmia is greater in women aged 4150 years
(199/100 000) than in those aged 1830 years (55/100 000), which
may be due to more prevalent AF and VT, whereas SVT seems stable
over time.535 Arrhythmias are also more frequent among women
with congenital heart disease, particularly atrial flutter, compared
with women without congenital defects.536
As substantive prospective or randomized studies are unavailable,
recommendations are primarily based on small cohorts or case
reports in conjunction with expert opinion.
14.1 Maternal, obstetric, and offspring
risk
SVT is associated with an increased risk of death during pregnancy,
and the reported frequency is 68 per 100 000 pregnancy-related hos-
pitalizations for any arrhythmia, 22 per 100 000 for SVT, 4 per
100 000 for atrial flutter, 27 per 100 000 for AF, 2 per 100 000 for
ventricular fibrillation, and 16 per 100 000 for VT.535
Identification and treatment of underlying conditions are the first
priorities. Although most of the exacerbations of SVT during preg-
nancy are benign and can be treated effectively with standard medical
therapy,537 the circumstances that should be considered include the
well-being of the foetus and the effects on labour, delivery, and lacta-
tion. The haemodynamic effect of tachycardia, as well as side effects
of treatments, must be balanced and addressed for the foetus.
Catheter ablation should therefore be considered before pregnancy
when possible in patients with a known history of symptomatic




Treatment with antiarrhythmic drugs for the prevention of SVT
should, in general, be reserved for SVTs causing haemodynamic com-
promise or significant symptoms. The major concern regarding the
use of antiarrhythmic drugs during pregnancy is potential adverse
effects on the foetus. While the first trimester is associated with the
greatest teratogenic risk, drug exposure later in pregnancy may result
in adverse effects on foetal growth and development, and on uterine
contractility, and an increased risk of pro-arrhythmia. The risks and
benefits of continuing vs. stopping medication must be carefully con-
sidered in terms of the risk of recurring SVT, and the potential for
haemodynamic compromise. Decisions should be individualized,
based on the clinical situation and possible additional structural heart
disease. Major controlled studies of antiarrhythmic drugs during preg-
nancy are lacking. If non-invasive manoeuvres fail, adenosine should
be the first-line drug for treatment if needed during the second and
third trimesters. There is a paucity of data on management of SVT in
the first trimester.542 All beta-blockers can cause bradycardia and
hypoglycaemia in the foetus. As beta-1 selective beta-blockers are
less likely to affect uterine relaxation, they are preferred.546 Maternal
use of beta-blockers in the first trimester has not been associated
with a large increase in the risk for overall or cardiac malforma-
tions.548,553 However, in the EUROmediCAT study, an association
between alpha/beta-adrenergic blocker use in the first trimester with
multicystic renal dysplasia was reported.554 There have been con-
cerns about ‘low weight for gestational age’ with beta-blockers,
although the effects reported may not be large enough to be of clini-
cal importance. Exposure to atenolol has been associated with a
Recommendations for the therapy of supraventricular tachycardia in pregnancy
Recommendation Classa Levelb
Catheter ablation is recommended in symptomatic women with recurrent SVT who plan to become pregnant.538 I C
Acute therapy
Immediate electrical cardioversion is recommended for any tachycardia with haemodynamic instability.539,540 I C
Vagal manoeuvres and, if these fail, adenosine are recommended for acute conversion of SVT.541,542 I C
An i.v. beta-1 selective blocker (except atenolol) should be considered for acute conversion or rate control of SVT.542,543 IIa C
i.v. digoxin in the latest pocket Gls version should be considered for rate control of AT if beta-blockers fail.542,543 IIa C
i.v. ibutilide in the latest pocket Gls version may be considered for termination of atrial flutter.544,545 IIb C
Chronic therapy
During the first trimester of pregnancy, it is recommended that all antiarrhythmic drugs should be avoided, if possible. I C
Beta-1 selective (except atenolol) beta-blockers or verapamil, in order of preference, should be considered for prevention of
SVT in patients without WPW syndrome.543,546548
IIa C
Flecainide or propafenone should be considered for prevention of SVT in patients with WPW syndrome, and without ischaemic
or structural heart disease.549
IIa C
Flecainide or propafenone in patients without ischaemic or structural heart disease should be considered if AV nodal blocking
agents fail to prevent SVT.533,543
IIa C
Digoxin or verapamil should be considered for rate control of AT if beta-blockers fail in patients without WPW syndrome.543 IIa C
Amiodarone is not recommended in pregnant women.153,543 III C
Fluoroless catheter ablation should be considered in cases of drug-refractory or poorly tolerated SVT, in experienced
centres.550552
IIa C
i.v. ibutilide is contraindicated in patients with prolonged QTc interval.









































.higher risk of infants born small for their gestational age compared
with metoprolol and propranolol, consistent with this association
not being a class effect.543,555 Diltiazem has been found to be terato-
genic in animals, with only limited human data, and its use is not gen-
erally recommended in pregnancy. Verapamil is considered safer
than diltiazem and could be used as a second-line drug.153,543
14.2.2 Electrical cardioversion
Electrical cardioversion should be the first choice when arrhythmias
are haemodynamically unstable. Cardioversion seems safe in all
phases of pregnancy as it does not compromise foetal blood flow,
and has low risk of inducing foetal arrhythmias or initiating pre-term
labour.539 The foetal heart rate should be routinely controlled after
cardioversion.
14.2.3 Catheter ablation
Catheter ablation should be postponed to the second trimester if
possible, but may be necessary in the case of drug-refractory and
poorly tolerated tachycardia. It should then be performed at an expe-
rienced centre using non-fluoroscopic electroanatomical mapping
and catheter navigation systems.556 Catheter ablation of recurrent,
drug-refractory AVNRT, AVRT, focal AT, and CTI-dependent atrial




Tachycardia-induced cardiomyopathy (TCM), or more accurately
arrhythmia-induced cardiomyopathy, is a reversible cause of impaired
LV function due to persistent tachycardia or very frequent ventricular
premature beats that can lead to HF and death. The incidence of
TCM is unknown but has been reported in all age groups, from foe-
tuses to the elderly.
15.2 Mechanism
The syndrome was initially described with PJRT, but we now know
that any chronic cardiac arrhythmia may cause TCM. Incessant
AVRTs due to septal APs, rapid AF, idiopathic VT, AT, and persistent
ectopic beats are best described.196,233,526,557563 In patients aged
<18 years, focal AT is the commonest cause.408
Rapid pacing in animal models induces cytoskeletal changes and
remodelling of the extracellular matrix attributed to abnormal cal-
cium cycling, increased catecholamines, decreased beta-1 adrenergic
receptor density, oxidative stress, depletion of myocardial energy
stores, and myocardial ischaemia due to increased heart rate.559,564
Endomyocardial biopsy specimens from patients with TCM exhibit
features distinct from those of other types of cardiomyopathy,
including deranged cardiomyocyte and mitochondrial morphology,
and macrophage-dominated cardiac inflammation.565 However, it has
not been fully established how the majority of patients with frequent
premature ventricular contractions have a benign course, whereas
<_30% of them may develop cardiomyopathy.566
15.3 Diagnosis
TCM is one of the very few reversible causes of HF and dilated cardi-
omyopathy, and should be considered in any patient with new onset
of LV dysfunction. In the presence of persistent or frequent tachycar-
dia, or frequent premature ventricular contractions, a high index of
suspicion should be maintained. The diagnosis is established by
excluding other causes of cardiomyopathy, and demonstrating recov-
ery of LV function after eradication of the arrhythmia or control of
the ventricular rate. Typically in TCM, LV ejection fraction is <30%,
LV end-diastolic diameter is <65 mm, and LV end-systolic diameter is
<50 mm.557 More dilated ventricular volumes suggest underlying
dilated cardiomyopathy, although some overlapping of the two con-
ditions can occur. In patients with suspected TCM, cardiac magnetic
resonance (CMR) is advisable to exclude intrinsic structural change.
Serial assessment of N-terminal pro-B-type natriuretic peptide (NT-
proBNP) and estimation of the ratio of NT-proBNP at baseline to
NT-proBNP during follow-up can help differentiate TCM from irre-
versible idiopathic dilated cardiomyopathy.
15.4 Therapy
In TCM, LV function frequently improves after 3 months of
restoration of a normal heart rate. In IST, beta-blockers are indicated.
Catheter ablation is indicated when TCM is due to another SVT.
When the tachycardia itself cannot be ablated, AV nodal ablation
Recommendations for the therapy of supraventricular
tachycardia in patients with suspected or established
heart failure due to tachycardiomyopathy
Recommendation Classa Levelb
Catheter ablation is recommended for TCM
due to SVT.196,233,418,525
I B
Beta-blockers (from the list with proved mor-
tality and morbidity benefits in HFrEF) are rec-
ommended for TCM due to SVT, when
catheter ablation fails or is not applicable.567
I A
It is recommended that TCM is considered in
a patient with reduced LV ejection fraction
with an elevated heart rate (>100
b.p.m.).557561
I B
24 h (or multiday) ambulatory ECG monitor-
ing should be considered for diagnosis of TCM
by identifying subclinical or intermittent
arrhythmias.526,557,568
IIa B
AV nodal ablation with subsequent pacing
(‘ablate and pace’), either biventricular or His-
bundle pacing, is recommended if the tachy-
cardia responsible for the TCM cannot be
ablated or controlled by
drugs.526,557,564,569572
I C
b.p.m. = beats per minute; ECG = electrocardiogram; HFrEF = heart failure with
reduced ejection fraction; LV = left ventricular; SVT = supraventricular tachycar-

































































..with either biventricular or His-bundle pacing is appropriate.569572
Long-term medical therapy with beta-blockers, and angiotensin-
converting enzyme inhibitors or angiotensin II receptor blockers, is
indicated before and after successful ablation for the known beneficial
effects of these drugs on the LV remodelling process. Given the risk
of recurrence of arrhythmias, long-term monitoring of patients is
recommended.
16 Supraventricular tachycardia in
sports
Athletes with frequent supraventricular arrhythmias should be
assessed to exclude the presence of an underlying cardiac disease,
electrolyte imbalance, thyroid dysfunction, and the use of stimulants
or performance-enhancing drugs. Table 13 outlines the recommenda-
tions for sports eligibility of patients with SVT.573,574
Ventricular pre-excitation (WPW syndrome) is a rare cause of
sudden cardiac death in young athletes.575 Although many individ-
uals with ventricular pre-excitation remain asymptomatic
throughout their lives, symptomatic AVRT may occur. Patients
with WPW may also develop other arrhythmias, such as AF, which
could degenerate into ventricular fibrillation and sudden cardiac
death. Because sports activity has been associated with an
increased risk of AF,576 athletes with ventricular pre-excitation
have an increased risk of sudden cardiac death if the AP has the
potential for fast antegrade conduction. Thus, catheter ablation of
the AP is currently recommended in symptomatic athletes with
ventricular pre-excitation. Asymptomatic athletes with intermit-
tent pre-excitation (at rest or during exercise) or abrupt disap-
pearance of pre-excitation during stress testing may be
considered to be at low risk (see section 11.3.11 for reservations),
but should be further evaluated as they may be eligible for com-
petitive sports activity. In asymptomatic athletes with ventricular
pre-excitation, invasive risk stratification should be conducted as
described in section 11.3.11 and catheter ablation should be
performed in those with high-risk features.577 Asymptomatic
patients stratified at low risk are allowed to practice competitive
sports.
AVNRT, orthodromic AVRT over a concealed AP, and AT are
not listed among the causes of sudden cardiac death during exer-
cise in patients with a structurally normal heart. However, their
occurrence during sports activity may be associated with very high
heart rate because of sympathetic stimulation and may cause hae-
modynamic impairment even in patients with structurally normal
hearts. Accordingly, catheter ablation should generally be recom-
mended for all athletes with a history of paroxysmal SVT. Athletes
with SVT who do not wish to undergo catheter ablation, or in
whom the procedure has been unsuccessful, may be considered
eligible for competitive sports activity if the arrhythmia is sporadic,
unrelated to cardiac disease, well tolerated, and unrelated to
exercise, and when the sports activity does not have a high intrin-
sic risk of loss of consciousness (such as divers, pilots, horse
riders, etc.).578
Treatment of paroxysmal SVT with beta-blockers or sodium chan-
nel blockers is discouraged in athletes, because these drugs may
reduce performance during sports and have limited ability to prevent
arrhythmia recurrence during sports activity. Moreover, beta-
blockers are listed by the World Anti-Doping Agency as prohibited
drugs in particular sports.
17 Supraventricular tachycardia
and driving restrictions
The frequency of which medical causes contribute to motor vehicle
accidents is not precisely known. Data on arrhythmias as a cause of
motor vehicle accidents are hard to obtain due to the difficulty of
documenting such events in the general population. However, the
proportion is believed to be small, with 1 - 3% of all motor vehicle
accidents established as being due to a driver’s sudden incapacita-
tion.579 Of these accidents, 5 - 10% are related to cardiac causes, with
Table 13 Recommendations for sports participation in athletes with ventricular pre-excitation and supraventricular
arrhythmias
Criteria for eligibility Eligibility
Premature atrial beats No symptoms, no cardiac disease All sports
AVRT or AF in the context of WPW syndrome Ablation is mandatory. Sports are allowed 1 month after
ablation if there are no recurrences
All sports
Asymptomatic ventricular pre-excitation Ablation is mandatory in patients at high risk. Sports are
allowed 1 month after ablation if there are no recurrences
All sports
Paroxysmal SVT (AVNRT, AVRT over
a concealed AP, and AT)
Ablation is recommended. Sports are allowed 1 month
after ablation if there are no recurrences
All sports
All sports, except those
with high intrinsic risk of
loss of consciousness
Ablation undesirable or not feasible
AF = atrial fibrillation; AP = accessory pathway; AT = atrial tachycardia; AVNRT = atrioventricular nodal re-entrant tachycardia; AVRT = atrioventricular re-entrant tachycardia;


























































..or without syncope, while <2% of cases of reported sudden driver
incapacitation have resulted in injury or death to bystanders, or other
road users.579
In 2013, a Working Group of the ESC published detailed recom-
mendations on driving restriction in patients with SVT (Table 14).580
Two groups of drivers are considered. Group 1 comprises drivers of
motorcycles, cars, and other small vehicles with and without a trailer.
Group 2 includes drivers of vehicles over 3500 kg or passenger-
carrying vehicles exceeding eight seats excluding the driver. Drivers
of taxicabs, small ambulances, and other vehicles form an intermedi-
ate category between the ordinary private driver and the vocational
driver.
18 Key messages
• Not all SVTs are arrhythmias of the young.
• Vagal manoeuvres and adenosine are the treatments of choice
for the acute therapy of SVT, and may also provide important
diagnostic information.
• Verapamil is not recommended in wide QRS-complex tachycar-
dia of unknown aetiology.
• Consider using ivabradine, when indicated, together with a beta-
blocker.
• In all re-entrant and most focal arrhythmias, catheter ablation
should be offered as an initial choice to patients, after having
explained in detail the potential risks and benefits.
• Patients with macro-re-entrant tachycardias following atrial sur-
gery should be referred to specialized centres for ablation.
• In post-AF ablation ATs, focal or macro-re-entrant, ablation
should be deferred for >_3 months after AF ablation, when
possible.
• Ablate AVNRT, typical or atypical, with lesions in the anatomical
area of the nodal extensions, either from the right or left
septum.
• AVNRT, typical or atypical, can now be ablated with almost no
risk of AV block.
• Do not use sotalol in patients with SVT.
• Do not use flecainide or propafenone in patients with LBBB, or
ischaemic or structural heart disease.
• Do not use amiodarone in pre-excited AF.
• One in five patients with asymptomatic pre-excitation will
develop an arrhythmia related to their AP during follow-up.
• The risk of cardiac arrest/ventricular fibrillation in a patient with
asymptomatic pre-excitation is 2.4 per 1000 person-years.
• Non-invasive screening may be used for risk stratification of
patients with asymptomatic pre-excitation, but its predictive abil-
ity remains modest.
• Invasive assessment with an EPS is recommended in patients with
asymptomatic pre-excitation who either have high-risk occupa-
tions or are competitive athletes.
• If a patient undergoes assessment with an EPS and is found to
have an AP with ‘high-risk’ characteristics, catheter ablation
should be performed.
• If possible, avoid all antiarrhythmic drugs during the first trimester
of pregnancy. If beta-blockers are necessary, use only beta-1
selective agents (but not atenolol).
• If ablation is necessary during pregnancy, use non-fluoroscopic
mapping.
• Consider TCM in patients with reduced LV function and SVT.
• Ablation is the treatment of choice for TCM due to SVT. AV
nodal ablation with subsequent biventricular or His-bundle pacing
(‘ablate and pace’) should be considered if the SVT cannot be
ablated.
19 Gaps in the evidence
• The distinction between triggered activity and enhanced automa-
ticity is not straightforward, as the two mechanisms share many
similar responses and characteristics, such as enhancement by
Table 14 European Working Group 2013 report on driving and cardiovascular disease: driving in arrhythmias and con-
duction disorders: supraventricular tachycardia
Conduction disorder/
arrhythmia
Group 1 Group 2
AF/atrial flutter/focal AT Driving may continue provided no history of syncope.
If history of syncope, driving must cease until the con-
dition has been satisfactorily controlled/treated.
Driving may continue provided no history of syncope and
anticoagulation guidelines are adhered to.
If history of syncope, driving must cease unless the under-
lying cause is treated and the risk of recurrence is low.
Rate control during tachycardia should be adequate.
Driving can only be resumed after medical assessment.
AVNRT, AVRT, and WPW If history of syncope, driving must cease until the con-
dition has been satisfactorily controlled/treated.
Driving may continue provided no history of syncope or
other significant symptoms (e.g. palpitations with
dizziness).
If so, driving must cease until the underlying cause is
treated so that the risk of recurrence is low.
In case of pre-excitation, driving may only be allowed after
specialist assessment.





























.adrenergic activation and suppressed by L-type Ca2þ current
blockade.
• Re-entrant circuits may be microscopic or simulate foci by sur-
face ‘breakthrough’ of transmural propagation. Thus, mapping
may be inadequate to distinguish them from automatic/triggered
activity.
• The exact circuit of AVNRT, the most common regular arrhyth-
mia in the human, remains unresolved.
• The potential role of connexin proteins in AVNRT, and SVT in
general, is under investigation.
• Both invasive and non-invasive tests for the risk assessment of
patients with asymptomatic pre-excitation have limitations, being
dependent on the autonomic tone. More accurate risk-stratifica-
tion models are needed.
• The proper management of asymptomatic pre-excitation and
strict catheter ablation indications have not been established.
• The genetics of SVT have not been adequately studied. There
has been evidence for familial forms of AVNRT, AVRT, sinus
tachycardia, and AT, but data are scarce.
• Novel electroanatomical mapping systems now allow the simulta-
neous visualization of activation and voltage. The implications
that this may have on characterizing the tachycardia substrate,
and not just the circuit, require future research.
• Mathematical modelling and numerical analysis of recorded
ECGs, using fast Fourier and Gaussian models, may be helpful for
the future of artificial intelligence applications in the differential
diagnosis of narrow and wide QRS-complex tachycardias, but
experience is limited.
20 ‘What to do’ and ‘what not to do’ messages from the Guidelines
‘What to do’ messages
Recommendations for the acute management of narrow QRS tachycardia in the absence of an established diagnosis
Recommendation Classa Levelb
Haemodynamically unstable patients
Synchronized direct-current cardioversion is recommended for haemodynamically unstable patients. I B
Haemodynamically stable patients
A 12-lead ECG during tachycardia is recommended. I C
Vagal manoeuvres, preferably in the supine position with leg elevation, are recommended. I B
Adenosine (618 mg i.v. bolus) is recommended if vagal manoeuvres fail. I B
Synchronized direct-current cardioversion is recommended when drug therapy fails to convert or control the tachycardia. I B
Recommendations for the acute management of wide QRS tachycardia in the absence of an established diagnosis
Haemodynamically unstable patients
Synchronized direct-current cardioversion is recommended in haemodynamically unstable patients. I B
Haemodynamically stable patients
A 12-lead ECG during tachycardia is recommended. I C
Vagal manoeuvres, preferably in the supine position with leg elevation, are recommended. I C
Synchronized direct-current cardioversion is recommended if drug therapy fails to convert or control the tachycardia. I B
Recommendations for the therapy of sinus tachycardias
Inappropriate sinus tachycardia
Evaluation and treatment of reversible causes is recommended.139,144,162 I C
Recommendations for the therapy of focal AT
Acute therapy
Haemodynamically unstable patients
Synchronized DC cardioversion is recommended for haemodynamically unstable patients. I B
Haemodynamically stable patients
Synchronized DC cardioversion is recommended when drug therapy fails to convert or control the tachycardia. I B
Chronic therapy
Catheter ablation is recommended for recurrent focal AT, especially if incessant or causing tachycardiomyopathy. I B
Recommendations for the therapy of multifocal AT
Acute therapy
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Recommendations for the therapy of multifocal AT
Anticoagulation as in AF is recommended for patients with atrial flutter and concomitant AF. I B
Acute therapy
Haemodynamically unstable patients
Synchronized DC cardioversion is recommended for haemodynamically unstable patients. I B
Haemodynamically stable patients
Intravenous ibutilide or i.v. or oral (in-hospital) dofetilide is recommended for conversion to sinus rhythm in the absence of QTc
interval prolongation.
I B
Low-energy (<_100 J biphasic) electrical cardioversion is recommended for conversion to sinus rhythm. I B




Catheter ablation is recommended for symptomatic, recurrent episodes of cavotricuspid isthmus-dependent flutter. I A
Catheter ablation in experienced centres is recommended for symptomatic, recurrent episodes of non-CTI-dependent flutter. I B
Catheter ablation is recommended in patients with persistent atrial flutter or in the presence of depressed LV systolic function
due to tachycardiomyopathy.
I B
Recommendations for the management of AVNRT
Acute therapy
Haemodynamically unstable patients
Synchronized DC cardioversion is recommended for haemodynamically unstable patients.86-88 I B
Haemodynamically stable patients
Vagal manoeuvres, preferably in the supine position with leg elevation, are recommended.41, 89-91 I B
Adenosine (618 mg i.v. bolus) is recommended if vagal manoeuvres fail.92-94 I B
Synchronized DC cardioversion is recommended when drug therapy fails to convert or control the tachycardia.87, 88 I B
Long-term therapy
Catheter ablation is recommended for symptomatic, recurrent AVNRT.208, 336-339 I B
Recommendations for the therapy of AVRT due to manifest or concealed APs
Acute therapy
Haemodynamically unstable patients
Synchronized DC cardioversion is recommended for haemodynamically unstable patients. I B
Haemodynamically stable patients
Vagal manoeuvres, preferably in the supine position with leg elevation, are recommended. I B
Adenosine (618 mg i.v. bolus) is recommended if vagal manoeuvres fail and the tachycardia is orthodromic. I B
Synchronized DC cardioversion is recommended when drug therapy fails to convert or control the tachycardia. I B
Chronic therapy
Catheter ablation of AP(s) is recommended in patients with symptomatic, recurrent AVRT. I B
Recommendations for the acute therapy of pre-excited AF
Haemodynamically unstable patients
Synchronized DC cardioversion is recommended in haemodynamically unstable patients. I B
Haemodynamically stable patients
Synchronized DC cardioversion is recommended if drug therapy fails to convert or control the tachycardia. I B
Recommendations for the management of patients with asymptomatic pre-excitation
Performance of an EPS, with the use of isoprenaline, is recommended to risk stratify individuals with asymptomatic pre-excitation
who have high risk occupations/hobbies,c and those who participate in competitive athletics.
I B
Catheter ablation is recommended in asymptomatic patients in whom electrophysiology testing with the use of isoprenaline iden-
tifies high-risk properties, such as SPERRI <_250 ms, AP ERP <_250 ms, multiple APs, and an inducible AP-mediated tachycardia.
I B
Catheter ablation is recommended in high-risk patients with asymptomatic pre-excitation after discussing the risks, especially of
heart block associated with ablation of anteroseptal or mid-septal APs, and benefits of the procedure.
I C
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Recommendations for the therapy of SVTs in congenital heart disease in adults
Anticoagulation for focal AT or atrial flutter should be similar to patients with AF. I C
Acute therapy
Haemodynamically unstable patients
Synchronized DC cardioversion is recommended for haemodynamically unstable patients. I B
Haemodynamically stable patients
Vagal manoeuvres, preferably in the supine position with leg elevation, are recommended. I B
Adenosine (618 mg i.v. bolus) is recommended if vagal manoeuvres fail. I B
Synchronized DC cardioversion is recommended when drug therapy fails to convert or control the tachycardia. I B
Recommendations for the therapy SVT in pregnancy
Catheter ablation is recommended in symptomatic women with recurrent SVT who plan to become pregnant. I C
Acute therapy
Immediate electrical cardioversion is recommended for any tachycardia with haemodynamic instability. I C
Vagal manoeuvres and, if these fail, adenosine are recommended for acute conversion of SVT. I C
Chronic therapy
During the first trimester of pregnancy it is recommended to avoid all antiarrhythmic drugs, if possible. I C
Recommendations for the therapy of SVT in patients with suspected or established heart failure due to tachycardiomyopathy
Recommendation Classa Levelb
Catheter ablation is recommended for tachycardiomyopathy due to SVT. I B
Beta-blockers (from the list with proven mortality and morbidity benefits in HFrEF) are recommended for tachycardiomyopathy
due to SVT, when catheter ablation fails or is not applicable.
I A
It is recommended to consider tachycardiomyopathy in patient with reduced LV ejection fraction with an elevated heart rate
(>100 bpm).
I B
AV nodal ablation with subsequent pacing (“ablate and pace”), either biventricular or His-bundle pacing, is recommended if the
tachycardia responsible for the tachycardiomyopathy cannot be ablated or controlled by drugs.
I C
‘What not to do’ messages
Recommendations for the acute management of wide QRS tachycardia in the absence of an established diagnosis
Verapamil is not recommended in wide QRS-complex tachycardia of unknown aetiology. III B
Recommendations for the therapy of MRATs
Acute therapy
Propafenone and flecainide are not recommended for conversion to sinus rhythm. III B
Recommendations for the therapy of AVRT due to manifest or concealed APs
Chronic therapy
Digoxin, beta-blockers, diltiazem, verapamil, and amiodarone are not recommended and are potentially harmful in patients with
pre-excited AF.
III B
Recommendations for the acute therapy of pre-excited AF
Haemodynamically stable patients
Amiodarone (i.v.) is not recommended. III B
Recommendations for the therapy of SVTs in congenital heart disease in adults
Chronic therapy
Sotalol is not recommended as a first-line antiarrhythmic drug as it is related to an increased risk of pro-arrhythmias and
mortality.
III C
Flecainide and propafenone are not recommended as first-line antiarrhythmic drugs in patients with ventricular dysfunction and
severe fibrosis.
III C
Recommendations for the therapy of SVT in pregnancy
Chronic therapy
Amiodarone is not recommended in pregnant women. III C
AF = atrial fibrillation; AP = accessory pathway; AT = atrial tachycardia; AVNRT = atrioventricular nodal re-entrant tachycardia; AVRT = atrioventricular re-entrant tachycardia;
CTI = cavotricuspid isthmus; DC = direct current; ECG = electrocardiogram; EPS = electrophysiology study; ERP = effective refractory period; HF = heart failure; i.v. = intrave-



































































































21 Areas for further research
With the advent of catheter ablation in the 1990s, resulting in the
successful elimination of APs in symptomatic patients, AVRT now
represents <20% of all SVTs.11,13 The frequency of AVNRT, which
used to account for 50% of all SVT cases,14 has changed to
30%,11,13 and the proliferation of AF ablation will unavoidably result
in more iatrogenic left atrial MRAT. Moreover, the prolonged survival
of paediatric and ACHD patients is expected to impose a further
challenge on electrophysiologists, who will encounter even more
complex MRATs. Several important advances in the field of anatomi-
cal and electrical mapping, as well as our appreciation of scar tissue
and the transmurality of ablation lesions, should improve our effi-
ciency in treating these patients.
The past decade has witnessed a rapid evolution of ablation equip-
ment and electrode-guiding systems, which has resulted in more con-
trollable and safer procedures. Intracardiac echocardiography, robotic
techniques, and sophisticated anatomical navigation systems have
been developed, and it is now possible to perform ablation without
exposing the operator to radiation and ergonomically unfavourable
positions.581 New materials for electrodes and other equipment have
allowed the concept of a radiation-free electrophysiology laboratory
with the use of CMR. The vision of a fully radiation-free, magnetic lab-
oratory in the future is not science fiction anymore.582
The revolution in computer technology offers not only improved
mapping and electrode-moving systems, but also the enhancement of
specific SVT classification schemes with fully automated algorithms
that may greatly assist emergency departments, ambulances, and
monitored patients.583 Mathematical modelling and numerical analy-
ses have also been employed in the investigation of the circuit of
AVNRT.317,329 Further analysis of recorded ECGs using fast Fourier
and Gaussian models may also provide useful diagnostic information
about the nature of the tachycardia. Novel electroanatomical map-
ping systems are being developed to assist the identification of the
tachycardia mechanism and optimal ablation site of SVT, and, espe-
cially, complex atrial macro-re-entrant tachycardias, with reduced flu-
oroscopy times.584589 Systems are now available that allow the
simultaneous visualization of activation and voltage. The implications
that these may have on characterizing the tachycardia substrate, and
not just the circuit, require future research.
New data on the genetics of SVT continually appear since the identifi-
cation of a missense mutation in the PRKAG2 gene, which encodes the
regulatory c-subunit of adenosine monophosphate (AMP)-activated
protein kinase, as a cause of familial WPW syndrome.590,591 The
R302Q mutation in PRKAG2 has been associated with Mahaim fibers.592
A novel form of WPW syndrome is associated with microdeletion of
the BMP2 gene, which encodes bone morphogenetic protein-2, a mem-
ber of the transforming growth factor-beta gene superfamily, and affects
the development of annulus fibrosus.593 Other rare, genetic forms of
pre-excitation have also been described.398 Whether this kind of
genetic predisposition translates into a higher ventricular fibrillation risk
remains to be seen. Genetic animal models of WPW that express muta-
tions (such as of the gene encoding the AMP-activated protein kinase)
responsible for a familial form of WPW syndrome with a phenotype
identical to that of the human syndrome have been developed, and may
provide insight into the development and properties of the cardiac con-
duction system and APs.594 Spontaneous AVNRT has also been
identified as a potential first clinical manifestation of concealed Brugada
syndrome, particularly in female patients.595 It has been postulated that
genetic variants that reduce the sodium current may predispose individ-
uals to expression of both phenotypes. Cellular electrophysiology is
now being integrated into genetic analysis. The coupling of whole-
exome sequencing with cellular electrophysiological functional analysis
may elucidate the underlying pathophysiological mechanism responsible
for certain phenotypes.596 Recently, a familial form of IST was shown to
be associated with a gain-of-function mutation in the HCN4 pacemaker
channel (R524Q), conferring an increased sensitivity to the second mes-
senger cyclic AMP, which is a key mediator in sympathetic modula-
tion.597 These developments may have important implications for a
more specific diagnostic and personalized therapeutic approach in SVT.
Future research should define actionable patient-specific molecular
arrhythmia mechanisms, clarify the responses of the underlying sub-
strates to interventions, and achieve selective supraventricular targeting
of specific arrhythmic mechanisms with drugs.
SVTs are not only an everyday clinical problem, with AVNRT being
the most common regular arrhythmia in humans. They also provide
the background for proper training of future electrophysiologists by
means of their well-defined circuits, in most cases, and predictable
responses in the electrophysiology laboratory. In the era of compu-
terized approaches that are now available for AF, complex AT, and
VT ablation, this is very important for a rational, Aristotelian
approach to the art of medicine.598
22 Supplementary data
Supplementary Data with additional Supplementary Figures and text
complementing the full text, as well as sections on the electrophysiologi-
cal mechanisms of SVT, tachycardia circuits, and cardiac anatomy for the
electrophysiologist, along with the related supplementary references, are
available on the European Heart Journal website and via the ESC website at
www.escardio.org/guidelines.
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Dobrev D, Erol Ç, Galderisi M, Gorenek B, Kriebel T, Lambiase P, Lancellotti P,
Lane DA, Lang I, Manolis AJ, Morais J, Moreno J, Piepoli MF, Rutten FH,
Sredniawa B, Zamorano JL, Zannad F. 2015 ESC Guidelines for the management
of patients with ventricular arrhythmias and the prevention of sudden cardiac
death. The Task Force for the Management of Patients with Ventricular
Arrhythmias and the Prevention of Sudden Cardiac Death of the European
Society of Cardiology (ESC) Endorsed by: Association for European Paediatric
and Congenital Cardiology (AEPC). Eur Heart J 2015;36:27932867.
132. Ortiz M, Martin A, Arribas F, Coll-Vinent B, Del Arco C, Peinado R, Almendral
J; PROCAMIO Study Investigators. Randomized comparison of intravenous pro-
cainamide vs. intravenous amiodarone for the acute treatment of tolerated
wide QRS tachycardia: the PROCAMIO study. Eur Heart J 2017;38:13291335.
133. Buxton AE, Marchlinski FE, Doherty JU, Flores B, Josephson ME. Hazards of intrave-
nous verapamil for sustained ventricular tachycardia. Am J Cardiol 1987;59:11071110.
134. Dancy M, Camm AJ, Ward D. Misdiagnosis of chronic recurrent ventricular
tachycardia. Lancet 1985;326:320323.
135. Crijns HJ, Lie KI. Haemodynamic deterioration after treatment with adenosine.
Br Heart J 1995;73:103.
136. Gorgels APM, van den Dool A, Hofs A, Mulleneers R, Smeets JLRM, Vos MA,
Wellens HJJ. Comparison of procainamide and lidocaine in terminating sus-
tained monomorphic ventricular tachycardia. Am J Cardiol 1996;78:4346.
137. Scheinman MM, Levine JH, Cannom DS, Friehling T, Kopelman HA, Chilson
DA, Platia EV, Wilber DJ, Kowey PR. Dose-ranging study of intravenous amio-
darone in patients with life-threatening ventricular tachyarrhythmias. Circulation
1995;92:32643272.
138. Levine JH, Massumi A, Scheinman MM, Winkle RA, Platia EV, Chilson DA,
Gomes JA, Woosley RL. Intravenous amiodarone for recurrent sustained hypo-
tensive ventricular tachyarrhythmias. J Am Coll Cardiol 1996;27:6775.
139. Olshansky B, Sullivan RM. Inappropriate sinus tachycardia. Europace
2019;21:194207.
140. Still A-M, Raatikainen P, Ylitalo A, Kauma H, Ik€aheimo M, Kes€aniemi YA,
Huikuri HV. Prevalence, characteristics and natural course of inappropriate
































































































141. Baruscotti M, Bucchi A, Milanesi R, Paina M, Barbuti A, Gnecchi-Ruscone T,
Bianco E, Vitali-Serdoz L, Cappato R, DiFrancesco D. A gain-of-function muta-
tion in the cardiac pacemaker HCN4 channel increasing cAMP sensitivity is
associated with familial Inappropriate Sinus Tachycardia. Eur Heart J
2017;38:280288.
142. Ruzieh M, Moustafa A, Sabbagh E, Karim MM, Karim S. Challenges in treatment
of inappropriate sinus tachycardia. Curr Cardiol Rev 2018;14:4244.
143. Brunner S, Herbel R, Drobesch C, Peters A, Massberg S, Kaab S, Sinner MF.
Alcohol consumption, sinus tachycardia, and cardiac arrhythmias at the Munich
Octoberfest: results from the Munich Beer Related Electrocardiogram Workup
Study (MunichBREW). Eur Heart J 2017;38:21002106.
144. Shen WK. How to manage patients with inappropriate sinus tachycardia. Heart
Rhythm 2005;2:10151019.
145. Foster MC, Levine PA. Use of verapamil to control an inappropriate chronic
sinus tachycardia. Chest 1984;85:697699.
146. Cappato R, Castelvecchio S, Ricci C, Bianco E, Vitali-Serdoz L, Gnecchi-
Ruscone T, Pittalis M, De Ambroggi L, Baruscotti M, Gaeta M, Furlanello F, Di
Francesco D, Lupo PP. Clinical efficacy of ivabradine in patients with inappropri-
ate sinus tachycardia: a prospective, randomized, placebo-controlled, double-
blind, crossover evaluation. J Am Coll Cardiol 2012;60:13231329.
147. Ptaszynski P, Kaczmarek K, Ruta J, Klingenheben T, Wranicz JK. Metoprolol suc-
cinate vs. ivabradine in the treatment of inappropriate sinus tachycardia in
patients unresponsive to previous pharmacological therapy. Europace
2013;15:116121.
148. Benezet-Mazuecos J, Rubio JM, FarrE J, Qui ~NOnes MA, Sanchez-Borque P,
MacIA E. Long-term outcomes of ivabradine in inappropriate sinus tachycardia
patients: appropriate efficacy or inappropriate patients. Pacing Clin Electrophysiol
2013;36:830836.
149. Calo L, Rebecchi M, Sette A, Martino A, de Ruvo E, Sciarra L, De Luca L,
Zuccaro LM, Giunta G, Ciccaglioni A, Lioy E, Fedele F. Efficacy of ivabradine
administration in patients affected by inappropriate sinus tachycardia. Heart
Rhythm 2010;7:13181323.
150. Ptaszynski P, Kaczmarek K, Ruta J, Klingenheben T, Wranicz JK. Ivabradine in
the treatment of inappropriate sinus tachycardia in patients after successful
radiofrequency catheter ablation of atrioventricular node slow pathway. Pacing
Clin Electrophysiol 2013;36:4249.
151. Dias da Silva VJ, Tobaldini E, Rocchetti M, Wu MA, Malfatto G, Montano N,
Zaza A. Modulation of sympathetic activity and heart rate variability by ivabra-
dine. Cardiovasc Res 2015;108:3138.
152. Ptaszynski P, Kaczmarek K, Ruta J, Klingenheben T, Cygankiewicz I, Wranicz JK.
Ivabradine in combination with metoprolol succinate in the treatment of inap-
propriate sinus tachycardia. J Cardiovasc Pharmacol Ther 2013;18:338344.
153. Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, Blomström-Lundqvist C,
Cıfkova R, De Bonis M, Iung B, Johnson MR, Kintscher U, Kranke P, Lang IM,
Morais J, Pieper PG, Presbitero P, Price S, Rosano GMC, Seeland U, Simoncini
T, Swan L, Warnes CA; ESC Scientific Document Group. 2018 ESC Guidelines
for the management of cardiovascular diseases during pregnancy. Eur Heart J
2018:39:31653241.
154. Yu J, Zhou Z, Tay-Sontheimer J, Levy RH, Ragueneau-Majlessi I. Risk of clinically
relevant pharmacokinetic-based drug-drug interactions with drugs approved by
the U.S. Food and Drug Administration between 2013 and 2016. Drug Metab
Dispos 2018;46:835845.
155. Man KC, Knight B, Tse H-F, Pelosi F, Michaud GF, Flemming M, Strickberger SA,
Morady F. Radiofrequency catheter ablation of inappropriate sinus tachycardia
guided by activation mapping. J Am Coll Cardiol 2000;35:451457.
156. Marrouche NF, Beheiry S, Tomassoni G, Cole C, Bash D, Dresing T, Saliba W,
Abdul-Karim A, Tchou P, Schweikert R, Leonelli F, Natale A. Three-dimensional
nonfluoroscopic mapping and ablation of inappropriate sinus tachycardia: pro-
cedural strategies and long-term outcome. J Am Coll Cardiol
2002;39:10461054.
157. Callans DJ, Ren J-F, Schwartzman D, Gottlieb CD, Chaudhry FA, Marchlinski FE.
Narrowing of the superior vena cavaright atrium junction during radiofre-
quency catheter ablation for inappropriate sinus tachycardia: analysis with intra-
cardiac echocardiography. J Am Coll Cardiol 1999;33:16671670.
158. Takemoto M, Mukai Y, Inoue S, Matoba T, Nishizaka M, Ide T, Chishaki A,
Sunagawa K. Usefulness of non-contact mapping for radiofrequency catheter
ablation of inappropriate sinus tachycardia: new procedural strategy and long-
term clinical outcome. Intern Med 2012;51:357362.
159. Koplan BA, Parkash R, Couper G, Stevenson WG. Combined epicardial-endo-
cardial approach to ablation of inappropriate sinus tachycardia. J Cardiovasc
Electrophysiol 2004;15:237240.
160. Jacobson JT, Kraus A, Lee R, Goldberger JJ. Epicardial/endocardial sinus node
ablation after failed endocardial ablation for the treatment of inappropriate
sinus tachycardia. J Cardiovasc Electrophysiol 2014;25:236241.
161. Rodrıguez-Ma~nero M, Kreidieh B, Al Rifai M, Ibarra-Cortez S, Schurmann P,
Alvarez PA, Fernandez-Lopez XA, Garcıa-Seara J, Martınez-Sande L, Gonzalez-
Juanatey JR, Valderrabano M. Ablation of inappropriate sinus tachycardia: a sys-
tematic review of the literature. JACC Clin Electrophysiol 2017;3:253265.
162. Klein I, Ojamaa K. Thyroid hormone and the cardiovascular system. N Engl J
Med 2001;344:501509.
163. Gomes JA, Hariman RJ, Kang PS, Chowdry IH. Sustained symptomatic sinus
node reentrant tachycardia: Incidence, clinical significance, electrophysiologic
observations and the effects of antiarrhythmic agents. J Am Coll Cardiol
1985;5:4557.
164. Malik AK, Ching CK, Liew R, Chong DT, Teo WS. Successful ablation of sinus
node reentrant tachycardia using remote magnetic navigation system. Europace
2012;14:455456.
165. Cossu SF, Steinberg JS. Supraventricular tachyarrhythmias involving the sinus
node: clinical and electrophysiologic characteristics. Prog Cardiovasc Dis
1998;41:5163.
166. Sanders WE Jr, Sorrentino RA, Greenfield RA, Shenasa H, Hamer ME, Wharton
JM. Catheter ablation of sinoatrial node reentrant tachycardia. J Am Coll Cardiol
1994;23:926934.
167. Fu Q, VanGundy TB, Shibata S, Auchus RJ, Williams GH, Levine BD. Exercise
training versus propranolol in the treatment of the postural orthostatic tachy-
cardia syndrome. Hypertension 2011;58:167175.
168. Fu Q, VanGundy TB, Galbreath MM, Shibata S, Jain M, Hastings JL, Bhella PS,
Levine BD. Cardiac origins of the postural orthostatic tachycardia syndrome.
J Am Coll Cardiol 2010;55:28582868.
169. Winker R, Barth A, Bidmon D, Ponocny I, Weber M, Mayr O, Robertson D,
Diedrich A, Maier R, Pilger A, Haber P, Rüdiger HW. Endurance exercise
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577. Heidbüchel H, Panhuyzen-Goedkoop N, Corrado D, Hoffmann E, Biffi A,
Delise P, Blomstrom-Lundqvist C, Vanhees L, Ivarhoff P, Dorwarth U, Pelliccia
A; Study Group on Sports Cardiology of the European Association for
Cardiovascular Prevention and Rehabilitation. Recommendations for participa-
tion in leisure-time physical activity and competitive sports in patients with
arrhythmias and potentially arrhythmogenic conditions Part I: supraventricular
arrhythmias and pacemakers. Eur J Cardiovasc Prev Rehabil 2006;13:475484.
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